EurekaMag
+ Translate
+ Most Popular
Advantages and disadvantages of bordeaux mixture and of lime-sulphur used on apples in the growing season
Observations on the Umaria marine bed
10 years of hearing conservation in the Royal Air Force
Chocolate crumb - dairy ingredient for milk chocolate
Effect of daily gelatin ingestion on human scalp hair
Comparison of rice bran and maize bran as feeds for growing and fattening pigs
The composition of pampas-grass (Cortaderia argentea.)
The Accraian Series:
The mechanism of the Liebermann-Burchard reaction of sterols and triterpenes and their esters
Cerebrovascular Doppler ultrasound studies (cv-Doppler)
Toria: PT-303 - first national variety
Hair growth promoting activity of tridax procumbens
Productivity of Pekin x Khaki Campbell ducks
A stable cytosolic expression of VH antibody fragment directed against PVY NIa protein in transgenic potato plant confers partial protection against the virus
Solar treatment of wheat loose smut
Swimmers itch in the Lake of Garda
Bactofugation and the Bactotherm process
The effects of prefrontal lobotomy on aggressive behavior in dogs
Visual rating scales for screening whorl-stage corn for resistance to fall armyworm
Breakdown of seamounts at the trench axis, viewed from gravity anomaly
Kooken; pennsylvania's toughest cave
Recovery of new dinosaur and other fossils from the Early Cretaceous Arundel Clay facies (Potomac Group) of central Maryland, U.S.A
Zubor horny (Bison bonasus) v prirodnych podmienkach Slovensku
The extended Widal test in the diagnosis of fevers due to Salmonella infection
Hair of the american mastodon indicates an adaptation to a semi aquatic habitat

List of PDF Full Texts available from EurekaMag Chapter 67137

Chapter 67137 contains a list of PDF Full Texts available from EurekaMag.




P.1.g.026 Contribution of 5-Ht and dopamine to the physiological and behavioural effects of mephedrone following binge dosing in the rat
, European Neuropsychopharmacology 24: S217-S218 (2014)

P.1.g.029 Acute stress increases the readily releasable pool of glutamate vesicles in cortical areas
, European Neuropsychopharmacology 24: S219-S220 (2014)

P.1.g.030 Pronounced dopaminergic dysregulation in dopamine transporter knockout rats
, European Neuropsychopharmacology 24: S220-S221 (2014)

P.1.g.032 Gsb-106, a low molecular weight dipeptide analogue of Bdnf, protected cells via the TrkB, Akt, Erk 1/2 activation
, European Neuropsychopharmacology 24: S221-S222 (2014)

P.1.g.034 The interaction of levetiracetam analgesia with morphine-induced tolerance in the tail-flick mouse model
, European Neuropsychopharmacology 24: S222-S223 (2014)

P.1.g.036 Effects of mood-stabilising drugs on dendritic outgrowth and synaptic protein levels in the primary hippocampal neurons
, European Neuropsychopharmacology 24: S223-S224 (2014)

P.1.g.037 Repeated stimulation of brain serotonergic system affects liver cytochrome P450
, European Neuropsychopharmacology 24: S224-S225 (2014)

P.1.g.039 Connexin channel inhibitor promotes the anti-hyperalgesic effect of amitriptyline in sciatic nerve-ligated rats
, European Neuropsychopharmacology 24: S225-S226 (2014)

P.1.g.041 Experimental studies of the analgesic effect of pregabalin
, European Neuropsychopharmacology 24: S226-S227 (2014)

P.1.g.042 Substantia nigra inputs modulate nigrotectal pathways during the organisation of defensive behaviour in a dangerous environment
, European Neuropsychopharmacology 24: S227-S228 (2014)

P.1.g.044 Trace amine-associated receptor 1 inhibits a hyperglutamatergic state induced by dopamine deficiency
, European Neuropsychopharmacology 24: S228-S229 (2014)

P.1.g.046 Neuroprotective effect of fluoxetine associated with Bcl-2 expression in an experimental model of ischemic stroke in mice
, European Neuropsychopharmacology 24: S229-S230 (2014)

P.1.g.047 Myracrodruon urundeuva Allemo, a Brazilian medicinal species, presents neuroprotective effects on a Parkinsons disease model, in rats
, European Neuropsychopharmacology 24: S230-S231 (2014)

P.1.g.049 Disruption of MekErk activation in brain during midazolam-induced sleep in mice
, European Neuropsychopharmacology 24: S231-S232 (2014)

P.1.g.052 Cariprazine demonstrates greater potency than aripiprazole in animal models of psychosis, cognitive impairment, and negative symptoms
, European Neuropsychopharmacology 24: S233-S234 (2014)

P.1.g.054 Effect of genetic and pharmacological blockade of Gaba receptors on a serotonergic regulation of stress
, European Neuropsychopharmacology 24: S234-S235 (2014)

P.1.g.057 Il-1Ra stabilises the thioldisulfide system in the brain tissues of rats with experimental diabetes and cerebral ischemia
, European Neuropsychopharmacology 24: S236-S237 (2014)

P.1.g.059 A novel analogue of fragment of vasopressin causes decrease of depression components in rats after neonatal intranasal injection
, European Neuropsychopharmacology 24: S237-S238 (2014)

P.1.g.061 Paliperidone palmitate versus haloperidol decanoate an animal study
, European Neuropsychopharmacology 24: S238-S239 (2014)

P.1.g.064 Effects of grape seed extract and vitamin E on oxidative stress and apoptosis in the hippocampus of rats with streptozotocin-induced diabetes
, European Neuropsychopharmacology 24: S240-S241 (2014)

P.1.g.067 The GalR1GalR2 heteroreceptor complex can be the receptor for galanin fragment 115
, European Neuropsychopharmacology 24: S242-S243 (2014)

P.1.g.069 D-serine prevents cognitive deficits caused by acute stress
, European Neuropsychopharmacology 24: S243-S244 (2014)

P.1.g.071 Interaction between serotonin 1A and 2A receptor subtypes in neuronal and lymphoblastoid cells
, European Neuropsychopharmacology 24: S244-S245 (2014)

P.1.g.074 Acquired binge-eating behaviour produces alterations in dopaminergic neurochemistry in the brains of rats
, European Neuropsychopharmacology 24: S246-S247 (2014)

P.1.g.076 The neuroprotective effect of Erythrina velutina on cerebral ischemia in mice
, European Neuropsychopharmacology 24: S247-S248 (2014)

P.1.g.079 Effect of a 5-Ht2A/2C receptor agonist on spinal glial activation
, European Neuropsychopharmacology 24: S249-S250 (2014)

P.1.g.081 Desloratadine exerts antitumor effect against glioma cell lines
, European Neuropsychopharmacology 24: S250-S251 (2014)

P.1.g.083 Effects of apocynin on retrograde memory dysfunction and glial response induced by transient global cerebral ischemia in rats
, European Neuropsychopharmacology 24: S251-S252 (2014)

P.1.g.086 Divergent actions of a Kv3 positive modulator on gamma frequency oscillations in the mammalian neocortex in vitro
, European Neuropsychopharmacology 24: S253-S254 (2014)

P.1.g.088 Prolyl endopeptidase inhibitor prevents changes in the monoaminergic systems in the brain of rats with anxiety-depressive state
, European Neuropsychopharmacology 24: S254-S255 (2014)

P.1.g.089 Ethanol modulates in a biphasic manner hyperpolarisation-activated currents (Ih) in rat hippocampal Ca3 pyramidal neurons
, European Neuropsychopharmacology 24: S255-S256 (2014)

P.1.g.091 The endocannabinoid system in the prelimbic cortex mediates fear-conditioned analgesia in rats
, European Neuropsychopharmacology 24: S256-S257 (2014)

P.1.g.092 Sexual dimorphism in rats perinatally treated with phencyclidine: effects of antipsychotics on bone mass and body composition
, European Neuropsychopharmacology 24: S257-S258 (2014)

P.1.g.095 Age-related neurodegenerative diseases: what we can learn from glaucoma
, European Neuropsychopharmacology 24: S259-S260 (2014)

P.1.g.097 The effects of some serotonin receptor antagonists on memory processes performance in rats
, European Neuropsychopharmacology 24: S260-S261 (2014)

P.1.g.098 Allomargaritarine as a basis for the creation of mitochondrial targeted potential neuroprotectors
, European Neuropsychopharmacology 24: S261-S262 (2014)

P.1.g.100 Validation of the extended simplified reference tissue model for pharmacological within-scan challenges in dynamic Pet
, European Neuropsychopharmacology 24: S262-S263 (2014)

P.1.g.102 Modulation of the conditioned emotional response by dorsal hippocampus Trpv1 receptor
, European Neuropsychopharmacology 24: S263-S264 (2014)

P.1.g.105 Effect of dietary zinc deprivation on expression of Nmda receptor subunits and depressive-like behaviour: a time-course study
, European Neuropsychopharmacology 24: S265-S266 (2014)

P.1.g.108 Differential regulation of synaptic plasticity markers and behaviour by histone deacetylase inhibitors
, European Neuropsychopharmacology 24: S267-S268 (2014)

P.1.g.110 Evaluation of oxidative stress of Cocos nucifera L. extract on the central nervous system of mice
, European Neuropsychopharmacology 24: S268-S269 (2014)

P.1.g.112 Mitochondrial impairment, apoptosis and autophagy in the rat brain as immediate and long term effects of perinatal phencyclidine treatment
, European Neuropsychopharmacology 24: S269-S270 (2014)

P.1.g.114 Anterior cingulum Nmda receptors modulate fear-induced antinociception evoked by Gabaergic dysfunction in posterior hypothalamus
, European Neuropsychopharmacology 24: S270-S271 (2014)

P.1.h.002 Asenapine and paliperidone exert antidepressant- and anxiolytic-like effects in mice
, European Neuropsychopharmacology 24: S271-S272 (2014)

P.1.h.004 Spatial long-term memory and modulation of Nmda receptor subunit expression in medial septal immunolesioned rats
, European Neuropsychopharmacology 24: S272-S273 (2014)

P.1.h.006 Modulation of Nr2B subunit expression of Nmda receptors in the hippocampus and spatial short-term memory by septohippocampal projections
, European Neuropsychopharmacology 24: S273-S274 (2014)

P.1.h.008 A new model of depression-like behaviour in rodents for screening of prospective drugs with antidepressant action
, European Neuropsychopharmacology 24: S274-S275 (2014)

P.1.h.011 The effects of subacute administration of buprenorphine and the novel opioid modulator samidorphan on home-cage locomotor activity in rats
, European Neuropsychopharmacology 24: S276-S277 (2014)

P.1.h.013 Involvement of Cck receptors in morphine-induced antinociception in an animal model of neuropathic pain
, European Neuropsychopharmacology 24: S277-S278 (2014)

P.1.h.015 Neurosteroid dehydroepiandrosterone improves active avoidance learning in the rat
, European Neuropsychopharmacology 24: S278-S279 (2014)

P.1.h.018 Mk-801 injection into pedunculopontine tegmental nucleus alters behaviour elicited by ipsilateral stimulation of the mesolimbic system
, European Neuropsychopharmacology 24: S280-S281 (2014)

P.1.h.020 Independent periaqueductal gray and hypothalamic circuits for flight response and oriented behaviours elicited by innate fear
, European Neuropsychopharmacology 24: S281-S282 (2014)

P.1.h.022 Effect of nucleus accumbens deep brain stimulation on impulsive choice: core versus shell
, European Neuropsychopharmacology 24: S282-S283 (2014)

P.1.h.026 Advanced paternal age as a risk factor for social deficits: from rats to humans
, European Neuropsychopharmacology 24: S284-S285 (2014)

P.1.h.028 Selenium supplementation may reduce impaired long-term potentiation and long-term depression induced by propylthiouracil treatment
, European Neuropsychopharmacology 24: S285-S286 (2014)

P.1.h.031 Dopamine is involved in the different copulatory patterns of Roman high and low avoidance rats: studies with apomorphine and haloperidol
, European Neuropsychopharmacology 24: S287-S288 (2014)

P.1.h.033 Influence of housing conditions on social defeat paradigm in mice
, European Neuropsychopharmacology 24: S288-S289 (2014)

P.1.h.035 The influence of electrical stimulation of raphe magnus on immunological parameters in the peripheral blood of rats a pilot study
, European Neuropsychopharmacology 24: S289-S290 (2014)

P.1.h.038 Early life stress and neuronal nitric oxide synthase deficiency: effects on affective behaviour
, European Neuropsychopharmacology 24: S291-S292 (2014)

P.1.h.040 Differential effects of prenatal stress in female 5-Htt deficient mice: towards molecular mechanisms of resilience
, European Neuropsychopharmacology 24: S292-S293 (2014)

P.1.h.042 Rolipram improves functional outcome in mice subjected to bilateral common carotid artery occlusion
, European Neuropsychopharmacology 24: S293-S294 (2014)

P.1.h.043 Chronic heart failure and depression: anhedonia, motivation deficits, and functional brain changes in mice with myocardial infarction
, European Neuropsychopharmacology 24: S294-S295 (2014)

P.1.h.045 Down syndrome model characterisation: gene expression after treatment with selective 5 Gabaa modulator and quantification of metabolites
, European Neuropsychopharmacology 24: S295-S296 (2014)

P.1.i.001 Altered event-related potentials during visual emotional stimulation in posttraumatic stress disorder
, European Neuropsychopharmacology 24: S296-S297 (2014)

P.1.i.002 Subcortical shape and diffusion tensor findings in children with Adhd with and without co-existing tic disorder
, European Neuropsychopharmacology 24: S297-S298 (2014)

P.1.i.004 Resting-state functional connectivity in temporal lobe epilepsy patients with affective symptoms
, European Neuropsychopharmacology 24: S298-S299 (2014)

P.1.i.006 Brain white matter connectivity associated with treatment response to paliperidone Er treatment in patients with schizophrenia
, European Neuropsychopharmacology 24: S299-S300 (2014)

P.1.i.007 Modulatory effects of cross-sex steroid hormones in the adult human brain: a voxel-based morphometry study
, European Neuropsychopharmacology 24: S300-S301 (2014)

P.1.i.009 Emotional and working memory in treatment resistant depression: a functional magnetic resonance imaging study
, European Neuropsychopharmacology 24: S301-S302 (2014)

P.1.i.011 The effects of the Vrk2 (rs2312147) gene on white matter connectivity in patients with schizophrenia
, European Neuropsychopharmacology 24: S302-S303 (2014)

P.1.i.012 Genetic modulation of acute effects of delta-9-tetrahydrocannabinol (Thc) on resting state brain function
, European Neuropsychopharmacology 24: S303-S304 (2014)

P.1.i.014 Neurostructural characteristics of child and adolescent schizophrenia and bipolar offspring: a comparative, longitudinal study
, European Neuropsychopharmacology 24: S304-S305 (2014)

P.1.i.015 Neural correlates of the anxiolytic effects of silexan
, European Neuropsychopharmacology 24: S305-S306 (2014)

P.1.i.017 Independent effects of acute tryptophan depletion on mood and cortical activation during working memory tasks
, European Neuropsychopharmacology 24: S306-S307 (2014)

P.1.i.020 A 3T functional magnetic resonance imaging study with N-back task to assess working memory activation in euthymic bipolar I and Ii patients
, European Neuropsychopharmacology 24: S308-S309 (2014)

P.1.i.022 Neural activity during the n-back working memory task predicts relapse risk in alcohol dependence
, European Neuropsychopharmacology 24: S309-S310 (2014)

P.1.i.023 Increased translocator protein distribution volume, a marker of microglial activation, in the brain during major depressive episodes
, European Neuropsychopharmacology 24: S310-S311 (2014)

P.1.i.025 Gray matter changes associated with factors of alexithymia in healthy young adults
, European Neuropsychopharmacology 24: S311-S312 (2014)

P.1.i.028 Effects of dexamphetamine on frontostriatal network connectivity in recreational users
, European Neuropsychopharmacology 24: S313-S314 (2014)

P.1.i.030 Neural substrates of irony comprehension: are there any gender differences?
, European Neuropsychopharmacology 24: S314-S315 (2014)

P.1.i.033 Predictors of Dbs response: the impact of anhedonia and dopamine
, European Neuropsychopharmacology 24: S316-S317 (2014)

P.1.i.035 Abnormalities within visual networks relate to differences in complex visual performance in pediatric autism spectrum disorder
, European Neuropsychopharmacology 24: S317-S318 (2014)

P.1.i.036 Frontal white matter alterations in panic disorder patients without comorbid conditions: a diffusion tensor imaging study
, European Neuropsychopharmacology 24: S318-S319 (2014)

P.1.j.001 Combined pharmacological intervention targeting the glucocorticoidadrenergicendocannabinoid circuitry induces a traumatic memory
, European Neuropsychopharmacology 24: S319-S320 (2014)

P.1.j.005 Infliximab rescues cognitive impairment induced by unpredictable chronic mild stress in a rat model of depression
, European Neuropsychopharmacology 24: S321-S322 (2014)

P.1.j.007 Short- and long-term alteration in cognitive functioning of patients with schizophrenia
, European Neuropsychopharmacology 24: S322-S323 (2014)

P.1.j.008 Cognitive insight in schizophrenia: study about 30 Tunisian patients
, European Neuropsychopharmacology 24: S323-S324 (2014)

P.1.j.010 Neuropsychological profiles in periventricular nodular heterotopia
, European Neuropsychopharmacology 24: S324-S325 (2014)

P.1.j.013 Nos1ex1f-Vntr alters prefrontal activation in a set shifting task
, European Neuropsychopharmacology 24: S326-S327 (2014)

P.1.j.015 The effects of brain radiotherapy on facial emotion recognition and association with hippocampal and frontal dosimetry
, European Neuropsychopharmacology 24: S327-S328 (2014)

P.1.j.018 Taar1 deficiency produces frontostriatal dysfunctions
, European Neuropsychopharmacology 24: S329-S330 (2014)

P.1.j.020 Characterisation of cognitive functioning in schizophrenia and schizoaffective disorder
, European Neuropsychopharmacology 24: S330-S331 (2014)

P.1.j.021 Mller Lyer illusion manifestation peculiarities among people with paranoid schizophrenia
, European Neuropsychopharmacology 24: S331-S332 (2014)

P.1.j.023 Cognitive impairment in schizophrenia and bipolar disorder during the lifetime
, European Neuropsychopharmacology 24: S332-S333 (2014)

P.1.j.024 Calcineurin inhibition has different effects on within- and between-session fear extinction in mice
, European Neuropsychopharmacology 24: S333-S334 (2014)

P.1.j.026 Effects of Hiv and childhood trauma on brain morphometry and neurocognitive function
, European Neuropsychopharmacology 24: S334-S335 (2014)

P.1.j.028 Behavioural and neural correlates of cognitive control in Parkinson's disease
, European Neuropsychopharmacology 24: S335-S336 (2014)

P.1.j.031 When passive feels active reduced motor predictions and hypersalience alter moving rubber hand illusion in delusion proneness
, European Neuropsychopharmacology 24: S337-S338 (2014)

P.1.j.033 Symptom provocation induces low-frequency oscillations in the ventral striatum of patients with obsessivecompulsive disorder
, European Neuropsychopharmacology 24: S338-S339 (2014)

P.1.j.037 Agmatine attenuates vascular dementia in ageing
, European Neuropsychopharmacology 24: S340-S341 (2014)

P.1.k.002 Changes in prescription pattern of aripiprazole among psychiatric inpatients
, European Neuropsychopharmacology 24: S341-S342 (2014)

P.1.k.004 Historical cohort study in psychiatric emergency care: 20072013
, European Neuropsychopharmacology 24: S342-S343 (2014)

P.1.k.005 The economic crisis and mental health
, European Neuropsychopharmacology 24: S343-S344 (2014)

P.1.k.007 From genes to temperament to culture: differential distribution of affective temperaments parallels cultural index scores
, European Neuropsychopharmacology 24: S344-S345 (2014)

P.1.k.010 Prevalence of eating disorders in patients admitted to a female-only psychiatric inpatient unit in the Uk
, European Neuropsychopharmacology 24: S346-S347 (2014)

P.1.k.012 Characteristics of impulse control disorders in a group of medical students
, European Neuropsychopharmacology 24: S347-S348 (2014)

P.1.k.014 Predictors for development of female sexual dysfunctions in postmenopause
, European Neuropsychopharmacology 24: S348-S349 (2014)

P.1.k.015 Childhood depression: screening among Egyptian school children
, European Neuropsychopharmacology 24: S349-S350 (2014)

P.1.k.017 Adult Adhd in a general psychiatric population
, European Neuropsychopharmacology 24: S350-S351 (2014)

P.1.k.019 Prevalence of Adhd in non-psychotic adult psychiatric care (Adpsyc): a multinational cross-sectional study in Europe
, European Neuropsychopharmacology 24: S351-S352 (2014)

P.1.k.022 Sexual function and emotional state of patients with chronic heart failure in Lithuania
, European Neuropsychopharmacology 24: S353-S354 (2014)

P.1.k.024 Associations between attentional control and suicidality in German soldiers after deployment in Afghanistan
, European Neuropsychopharmacology 24: S354-S355 (2014)

P.1.k.025 Pitfalls of using absolute risk score for risk assessment and subtyping
, European Neuropsychopharmacology 24: S355-S356 (2014)

P.1.k.027 The disease network of mental disorders in Korea
, European Neuropsychopharmacology 24: S356-S357 (2014)

P.1.k.029 Psychiatric disorders in intensive care unit post cardio-surgery
, European Neuropsychopharmacology 24: S357-S358 (2014)

P.1.k.032 Associations of obstructive sleep apnea with anxiety and depression symptoms in male patients with coronary artery disease
, European Neuropsychopharmacology 24: S359-S360 (2014)

P.1.l.001 Publication pressure and scientific misconduct: implications for medical science
, European Neuropsychopharmacology 24: S360-S361 (2014)

P.2.a.002 Effect of cognitive behavioural therapy, and antidepressant medications on management strategies for cardiovascular diseases
, European Neuropsychopharmacology 24: S361-S362 (2014)

P.2.a.003 Anxiety and depression symptoms among patients with type 2 diabetes mellitus and poor glycaemia control
, European Neuropsychopharmacology 24: S362-S363 (2014)

P.2.a.005 Blockade of D1 dopaminergic receptors corrects depression-like behaviour in gonadectomised rats treated with a low dose of testosterone
, European Neuropsychopharmacology 24: S363-S364 (2014)

P.2.a.008 Correlation between levels of Akt1/Gsk-3 signaling pathway proteins and severity of depressive symptoms
, European Neuropsychopharmacology 24: S365-S366 (2014)

P.2.a.010 Buprenorphine in combination with samidorphan (Alks 33) results in antidepressive-like effects in two distinct rat models
, European Neuropsychopharmacology 24: S366-S367 (2014)

P.2.a.013 Antidepressant like effect of losartan infused into the ventral hippocampus
, European Neuropsychopharmacology 24: S368-S369 (2014)

P.2.a.015 Vortioxetine's reduced disruption of sleepwake rhythms involves 5-Ht3 receptor antagonism a study in rats
, European Neuropsychopharmacology 24: S369-S370 (2014)

P.2.a.018 Dysfunctional inhibitory mechanisms in locus coeruleus neurons of the Wistar Kyoto rat
, European Neuropsychopharmacology 24: S371-S372 (2014)

P.2.a.020 Hippocampal P2X7 receptor expression is modulated by stress and antidepressant treatment in the learned helplessness model
, European Neuropsychopharmacology 24: S372-S373 (2014)

P.2.a.021 Genome-wide association study of antidepressant-induced sexual dysfunction in depressed males
, European Neuropsychopharmacology 24: S373-S374 (2014)

P.2.a.023 Common and specific blood microRna alterations in unipolar and bipolar depression
, European Neuropsychopharmacology 24: S374-S375 (2014)

P.2.a.024 Regulation of Hdac5 and Sirt2 by chronic stress and imipramine treatment in the prefrontal cortex
, European Neuropsychopharmacology 24: S375-S376 (2014)

P.2.a.026 Zinc deficiency versus Gpr39-zinc receptor knockout mice in the pathophysiology of depression
, European Neuropsychopharmacology 24: S376-S377 (2014)

P.2.b.002 Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines
, European Neuropsychopharmacology 24: S378-S379 (2014)

P.2.b.005 Effects of vilazodone on sexual dysfunction in major depressive disorder: randomised, double-blind trial with placebo and active controls
, European Neuropsychopharmacology 24: S380-S381 (2014)

P.2.b.007 Prevalence and psychiatric correlates of suicidal ideation in primary care patients: gender differences
, European Neuropsychopharmacology 24: S381-S382 (2014)

P.2.b.011 Stable autobiographical memory function in magnetic seizure therapy
, European Neuropsychopharmacology 24: S383-S384 (2014)

P.2.b.013 Socio-demographic and clinical predictors of antidepressant remission and response in treatment resistant depression
, European Neuropsychopharmacology 24: S384-S385 (2014)

P.2.b.014 Modulation of limbicprefrontal connectivity by electroconvulsive therapy in depression: a structural equation modeling approach
, European Neuropsychopharmacology 24: S385-S386 (2014)

P.2.b.016 Efficacy and safety of vilazodone 20 mg and 40 mg in major depressive disorder (Mdd): a randomised, double-blind, placebo- and active-controlled trial
, European Neuropsychopharmacology 24: S386-S387 (2014)

P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study
, European Neuropsychopharmacology 24: S387-S388 (2014)

P.2.b.019 The complexity of genetic effects in pharmacogenetics: focus on neuroplasticity, environmental stress and response to antidepressants
, European Neuropsychopharmacology 24: S388-S389 (2014)

P.2.b.020 Comparative analysis of pregabalin and buspirone as adjunctive agents in major depressive disorder partially responsive to Ssris
, European Neuropsychopharmacology 24: S389-S390 (2014)

P.2.b.022 Different genes modulate risk for depression after childhood maltreatment and recent negative life events
, European Neuropsychopharmacology 24: S390-S391 (2014)

P.2.b.023 A single dose of mirtazapine modulates neuronal responses to spoken emotional narratives in healthy volunteers
, European Neuropsychopharmacology 24: S391-S392 (2014)

P.2.b.025 Depression in people with early onset of somatic illness analysis of 1970 British Cohort Study
, European Neuropsychopharmacology 24: S392-S393 (2014)

P.2.b.028 Agomelatine antidepressant activity and serum concentration of brain-derived neurotrophic factor (Bdnf): a positive correlation
, European Neuropsychopharmacology 24: S394-S395 (2014)

P.2.b.030 Interaction between depression remission status and salivary cortisol in relation to cognitive function in major depressive disorder
, European Neuropsychopharmacology 24: S395-S396 (2014)

P.2.b.031 Longitudinal interplay between paroxetine response, cortisol and fatty acid metabolism in major depressive disorder
, European Neuropsychopharmacology 24: S396-S397 (2014)

P.2.b.032 Serum brain-derived neurotrophic factor and symptom improvements post-ketamine treatment in treatment-resistant depression
, European Neuropsychopharmacology 24: S397-S398 (2014)

P.2.b.034 Affective disorders and epigenetics: study of possible mechanisms and biological targets
, European Neuropsychopharmacology 24: S398-S399 (2014)

P.2.b.036 Attachment style, alexithymia and social support affect emotional states and experiences
, European Neuropsychopharmacology 24: S399-S400 (2014)

P.2.b.037 Increase of alertness correlates with early brain-derived neurotrophic factor serum level rise and treatment outcome in major depression
, European Neuropsychopharmacology 24: S400-S401 (2014)

P.2.b.039 Different serum levels of brain-derived neurotrophic factor in first depressive episode: results from Bdnf studies in Macedonia and Bulgaria
, European Neuropsychopharmacology 24: S401-S402 (2014)

P.2.b.040 Mr and Gr balance predicts treatment outcome in treatment resistant depression
, European Neuropsychopharmacology 24: S402-S403 (2014)

P.2.b.042 Sustained efficacy and safety of agomelatine versus placebo over 24 weeks in elderly out-patients suffering from major depressive disorder
, European Neuropsychopharmacology 24: S403-S404 (2014)

P.2.b.043 Hypertension, depressive symptoms, and risk behaviors: results from a national health survey
, European Neuropsychopharmacology 24: S404-S405 (2014)

P.2.b.045 Efficacy of 3 agomelatine dose regimens versus placebo on the core symptoms of depression and functioning
, European Neuropsychopharmacology 24: S405-S406 (2014)

P.2.b.047 Efficacy of agomelatine in everyday clinical practice: results from a pan-Hellenic study: Sesame
, European Neuropsychopharmacology 24: S406-S407 (2014)

P.2.c.001 Multi-level biomarker analysis of nitric oxide synthase isoforms in bipolar disorder and adult Adhd
, European Neuropsychopharmacology 24: S407-S408 (2014)

P.2.c.002 Asenapine effects on dorsal raphe 5-Ht7 receptor responsiveness and in animal models of mania and resistant depression
, European Neuropsychopharmacology 24: S408-S409 (2014)

P.2.c.004 The receptor P2X7 participates in the amphetamine-induced increase of a proinflammatory environment in an animal model of mania
, European Neuropsychopharmacology 24: S409-S410 (2014)

P.2.c.006 What does lithium do to your creatinine?
, European Neuropsychopharmacology 24: S410-S411 (2014)

P.2.c.007 An international multicenter study of areas of the corpus callosum in bipolar disorder with and without psychotic features
, European Neuropsychopharmacology 24: S411-S412 (2014)

P.2.c.009 Epigenetically-induced modulation of the stress axis associated with the progression of bipolar disorder
, European Neuropsychopharmacology 24: S412-S413 (2014)

P.2.d.001 Investigation of bipolar subtypes which have been proposed to have different genetic etiology with respect to neurocognitive functions
, European Neuropsychopharmacology 24: S413-S414 (2014)

P.2.d.003 Wave-bd a large observational ambispective study: comparative results between the Romanian cohort and the total study population
, European Neuropsychopharmacology 24: S414-S415 (2014)

P.2.d.005 The current state of maintenance treatments for bipolar patients: a focus on the transition from acute treatments
, European Neuropsychopharmacology 24: S415-S416 (2014)

P.2.d.007 Misdiagnosis and role of duration of untreated illness (Dui)/untreated psychosis (Dup) in psychotic bipolar patients
, European Neuropsychopharmacology 24: S416-S417 (2014)

P.2.d.008 Cognitive deficits and subjective well-being in bipolar disorder
, European Neuropsychopharmacology 24: S417-S418 (2014)

P.2.d.010 Assessment of suicidal behaviour in bipolar disorder
, European Neuropsychopharmacology 24: S418-S419 (2014)

P.2.d.013 Evaluating depressive symptoms in mania study using a structured diagnostic tool, the Dsm-5 with mixed features specifier Mini module
, European Neuropsychopharmacology 24: S420-S421 (2014)

P.2.d.015 Mood disorders in the offspring of lithium treated bipolar patients clinical and neurobiological correlates
, European Neuropsychopharmacology 24: S421-S422 (2014)

P.2.d.017 Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder
, European Neuropsychopharmacology 24: S422-S423 (2014)

P.2.d.018 Sense of coherence as a predictor of suicide attempts in bipolar disorder
, European Neuropsychopharmacology 24: S423-S424 (2014)

P.2.d.020 Impact of alcohol use disorder in a sample of bipolar patients
, European Neuropsychopharmacology 24: S424-S425 (2014)

P.2.d.021 Understanding the real-world cost and burden of mania: the Manacor study
, European Neuropsychopharmacology 24: S425-S426 (2014)

P.2.d.023 Safety and tolerability of cariprazine in patients with acute bipolar mania: pooled analysis of 3 phase Ii/Iii pivotal studies
, European Neuropsychopharmacology 24: S426-S427 (2014)

P.2.d.025 Naturalistic study of either lithium or valproate in combination treatment with antipsychotics for pure manic inpatients
, European Neuropsychopharmacology 24: S427-S428 (2014)

P.2.d.028 Microglial activation in mood stabilised bipolar disorder patients
, European Neuropsychopharmacology 24: S429-S430 (2014)

P.2.d.030 Effect of total sleep deprivation and light therapy on corticolimbic connectivity in bipolar depression: a dynamic causal modeling study
, European Neuropsychopharmacology 24: S430-S431 (2014)

P.2.d.031 Predictors for manic switch at depressive episodes in bipolar disorder: the Systematic Treatment Enhancement Program for Bipolar Disorder
, European Neuropsychopharmacology 24: S431-S432 (2014)

P.2.d.033 Staging bipolar disorder: biological, clinical and functional correlates
, European Neuropsychopharmacology 24: S432-S433 (2014)

P.2.d.035 Base excision repair and oxidative Dna damage in patients with bipolar disorder
, European Neuropsychopharmacology 24: S433-S434 (2014)

P.2.d.036 Relationship between premorbid adjustment and functionality in mixed episodes of bipolar disorder
, European Neuropsychopharmacology 24: S434-S435 (2014)

P.2.d.038 Oxidative Dna base damage in bipolar disorder
, European Neuropsychopharmacology 24: S435-S436 (2014)

P.2.d.039 Functional remediation in bipolar Ii patients: improvement of functioning and subsyndromal symptoms
, European Neuropsychopharmacology 24: S436-S437 (2014)

P.2.d.041 Determinants of acute stress reactivity in euthymic bipolar disorder patients and their unaffected siblings
, European Neuropsychopharmacology 24: S437-S438 (2014)

P.2.d.043 A naturalistic study of antipsychotic-induced weight gain in bipolar disorder
, European Neuropsychopharmacology 24: S438-S439 (2014)

P.2.d.046 A Dti-tractography study of the uncinate fasciculus in schizophrenia and bipolar disorder: preliminary results
, European Neuropsychopharmacology 24: S440-S441 (2014)

P.2.d.048 Comt modulates working memory and impulsivity control in bipolar disorder
, European Neuropsychopharmacology 24: S441-S442 (2014)

P.2.d.049 The neurocognitive profile in adult bipolar disorder and Adhd
, European Neuropsychopharmacology 24: S442-S443 (2014)

P.2.d.051 Lurasidone in bipolar I depression: a 24 week, open-label extension study
, European Neuropsychopharmacology 24: S443-S444 (2014)

P.2.d.052 Lurasidone treatment for bipolar I depression: effect on core depression symptoms
, European Neuropsychopharmacology 24: S444-S445 (2014)

P.2.d.054 A pilot, open-label, 8-week study evaluating the efficacy of adjunctive minocycline for the treatment of bipolar I/Ii depression
, European Neuropsychopharmacology 24: S445-S446 (2014)

P.2.d.056 Verbal fluency deficits in patients with schizophrenia, psychotic bipolar disorder and their unaffected relatives
, European Neuropsychopharmacology 24: S446-S447 (2014)

P.2.e.003 The impact of antipsychotic drugs in depression: a role for adult neurogenesis?
, European Neuropsychopharmacology 24: S448-S449 (2014)

P.2.e.005 Regulation of clock gene expression in the chronic mild stress model: modulatory activity of the novel drug lurasidone
, European Neuropsychopharmacology 24: S449-S450 (2014)

P.2.e.007 Inflammasome complex is implicated in the severity of major depressive disorder
, European Neuropsychopharmacology 24: S450-S451 (2014)

P.2.f.001 Pharmacological treatment of depression with headache disorders: an appraisal of cost effectiveness and cost utility of antidepressants
, European Neuropsychopharmacology 24: S451-S452 (2014)

P.2.f.003 Comparison of aripiprazole augmentation versus bupropion combination for patient with major depressive disorder
, European Neuropsychopharmacology 24: S452-S453 (2014)

P.2.f.005 Efficacy and safety of a novel mGlu2 receptor positive allosteric modulator as an adjunctive treatment in anxious depression
, European Neuropsychopharmacology 24: S453-S454 (2014)

P.2.f.006 Better sexual acceptability of agomelatine compared to escitalopram in healthy volunteers during a 9-week placebo-controlled trial
, European Neuropsychopharmacology 24: S454-S455 (2014)

P.2.f.008 Ssri dose escalation versus duloxetine in treatment of major depressive disorder not responding to initial Ssri
, European Neuropsychopharmacology 24: S455-S456 (2014)

P.2.f.009 The efficacy of levomilnacipran extended-release (Er) in the treatment of patients with depression-associated fatigue symptoms
, European Neuropsychopharmacology 24: S456-S457 (2014)

P.2.f.011 Socio-demographic and clinical predictors of non response/non remission in treatment resistant depressed patients: a systematic review
, European Neuropsychopharmacology 24: S457-S458 (2014)

P.2.f.013 Effects of agomelatine compared to escitalopram on motivation in healthy male and female volunteers after 9 weeks of treatment
, European Neuropsychopharmacology 24: S458-S459 (2014)

P.2.f.014 Levomilnacipran inhibits both norepinephrine and serotonin reuptake across the clinical dose range
, European Neuropsychopharmacology 24: S459-S460 (2014)

P.2.f.017 Agomelatine versus desvenlafaxine versus bupropion Xr in the treatment of anhedonia in major depressive disorder
, European Neuropsychopharmacology 24: S461-S462 (2014)

P.2.f.019 Effect of Cyp2D6*10 polymorphism on mirtazapine metabolism in Japanese psychiatric patients
, European Neuropsychopharmacology 24: S462-S463 (2014)

P.2.f.020 The efficacy of vortioxetine in treating patients with severe depression or with depression and high level of anxiety symptoms
, European Neuropsychopharmacology 24: S463-S464 (2014)

P.2.f.022 Vortioxetine versus escitalopram in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction
, European Neuropsychopharmacology 24: S464-S465 (2014)

P.2.f.023 The efficacy of vortioxetine in the treatment of patients with major depressive disorder (Mdd) in short-term placebo-controlled studies: a meta-analysis of 11 studies
, European Neuropsychopharmacology 24: S465-S466 (2014)

P.2.f.025 Venlafaxine in depressive disorder comorbid with generalized anxiety disorder
, European Neuropsychopharmacology 24: S466-S467 (2014)

P.2.g.002 Depression and body image dissatisfaction in burn reconstruction patients in State Burn Centre of Riga
, European Neuropsychopharmacology 24: S469-S470 (2014)

P.2.g.004 Vortioxetine modulates Gaba and glutamate marker expression in a subchronic Pcp model of impaired executive functioning in rats
, European Neuropsychopharmacology 24: S470-S471 (2014)

P.2.g.005 Implication of coenzyme Q in mood disorder
, European Neuropsychopharmacology 24: S471-S472 (2014)

P.2.h.001 The prevalence of diabetes with the use of antidepressants
, European Neuropsychopharmacology 24: S472-S473 (2014)

P.2.h.004 Risk factors for suicidal ideation among patients with complex regional pain syndrome
, European Neuropsychopharmacology 24: S474-S475 (2014)

P.2.h.007 Characteristics of fatigue and depressive symptoms in haemodialysis patients
, European Neuropsychopharmacology 24: S476-S477 (2014)

P.2.h.009 Relationship of depression, anxiety and circulating endothelial progenitor cells in patients with acute coronary syndrome
, European Neuropsychopharmacology 24: S477-S478 (2014)

P.2.h.010 Association between thyroid stimulation hormone levels and risk of depression among general population with normal range free T4 levels
, European Neuropsychopharmacology 24: S478-S479 (2014)

P.2.h.012 Gluten sensitivity, celiac disease and mood disorders
, European Neuropsychopharmacology 24: S479-S480 (2014)

P.2.h.014 The relevance of oxidative stress status in first episode and recurrent depression
, European Neuropsychopharmacology 24: S480-S481 (2014)

P.2.h.015 Pharmacologic treatment strategies in premenstrual dysphoric disorder
, European Neuropsychopharmacology 24: S481-S482 (2014)

P.2.h.017 Are anxiety and depression differently associated with interpersonal relationship problems?
, European Neuropsychopharmacology 24: S482-S483 (2014)

P.3.a.001 Selective up-regulation of serotonin 5-Ht2A receptor coupling to Gi1-proteins in postmortem brain of subjects with schizophrenia
, European Neuropsychopharmacology 24: S483-S484 (2014)

P.3.a.004 Metabolic syndrome in patients with schizophrenia is associated with poor cognitive performance and poor premorbid school performance
, European Neuropsychopharmacology 24: S485-S486 (2014)

P.3.a.006 Tardive dyskinesia, dehydroepiandrosterone sulfate and cytochrome P450c17 gene polymorphism in psychiatric inpatients
, European Neuropsychopharmacology 24: S486-S487 (2014)

P.3.a.007 The interaction between Nos-I and Nos1Ap in dendrite development: implications for schizophrenia
, European Neuropsychopharmacology 24: S487-S488 (2014)

P.3.a.010 The involvement of Grm3 gene polymorphic loci in schizophrenia
, European Neuropsychopharmacology 24: S489-S490 (2014)

P.3.b.001 Risk factors for suicide in schizophrenia: systematic review and clinical recommendations
, European Neuropsychopharmacology 24: S490-S491 (2014)

P.3.b.002 Long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome
, European Neuropsychopharmacology 24: S491-S492 (2014)

P.3.b.005 Predictors of quality of life in individuals with schizophrenia
, European Neuropsychopharmacology 24: S493-S494 (2014)

P.3.b.007 Altered dorsolateral prefrontal cortex glutamate and striatal dopamine relationship in subjects at ultra high risk of psychosis
, European Neuropsychopharmacology 24: S494-S495 (2014)

P.3.b.010 Long-term drug adherence in first-episode psychosis: the role of cannabis use and involuntary admission
, European Neuropsychopharmacology 24: S496-S497 (2014)

P.3.b.011 Subjective well-being and experiential negative symptoms in schizophrenia
, European Neuropsychopharmacology 24: S497-S498 (2014)

P.3.b.013 Disrupted effective connectivity of emotional circuitry in schizophrenia: a dynamic causal modeling study
, European Neuropsychopharmacology 24: S498-S499 (2014)

P.3.b.015 Attitudes toward maintenance therapy among schizophrenia outpatients
, European Neuropsychopharmacology 24: S499-S500 (2014)

P.3.b.017 Second language reflects more psychopathology but compensates the verbal fluency in bilinguals with schizophrenia
, European Neuropsychopharmacology 24: S500-S501 (2014)

P.3.b.018 Posthoc analysis of patient relapse rates when switching from risperidone or other antipsychotics to paliperidone palmitate
, European Neuropsychopharmacology 24: S501-S502 (2014)

P.3.b.020 Long acting paliperidone palmitate a service evaluation of its use in clinical practice and its effects on hospital stay
, European Neuropsychopharmacology 24: S502-S503 (2014)

P.3.b.023 Reduced albumin plasma levels mediate the relationship between life stress and the risk of psychosis transition in at-risk mental states
, European Neuropsychopharmacology 24: S504-S505 (2014)

P.3.b.025 Plasma levels of risperidone in relation to dose, clinical improvement and side-effects in first-episode psychosis
, European Neuropsychopharmacology 24: S505-S506 (2014)

P.3.b.026 Relationship between psychopathology and interleukins 6 and 10 in acute paranoid schizophrenia
, European Neuropsychopharmacology 24: S506-S507 (2014)

P.3.b.030 Azd8529, a positive allosteric modulator at the Mgglur2 receptor, does not improve symptoms in schizophrenia: a proof of principle study
, European Neuropsychopharmacology 24: S508-S509 (2014)

P.3.b.032 Evaluation of preferences of chimeric, reversed and normal self-face in patients with schizophrenia and healthy controls a pilot study
, European Neuropsychopharmacology 24: S509-S510 (2014)

P.3.b.035 Psychotropics in emergency therapy in Hungary: a comparison with international trends
, European Neuropsychopharmacology 24: S511-S512 (2014)

P.3.b.037 Convergence insufficiency in schizophrenia and its relationship with cerebellar symptoms
, European Neuropsychopharmacology 24: S512-S513 (2014)

P.3.b.039 Predictors of adherence to antipsychotic treatment in first episode schizophrenia results of the Romanian cohort in the Eufest study
, European Neuropsychopharmacology 24: S513-S514 (2014)

P.3.b.040 The correlation of therapeutic adherence among adolescent and adult patients with psychosis using a Hplc&Lc-Ms method
, European Neuropsychopharmacology 24: S514-S515 (2014)

P.3.c.002 Kv3 channel modulation alleviates cognitive dysfunction and negative symptoms in an animal model of schizophrenia
, European Neuropsychopharmacology 24: S515-S516 (2014)

P.3.c.005 Clozapine and expression of the neurodevelopmental genes: a pilot study
, European Neuropsychopharmacology 24: S517-S518 (2014)

P.3.c.007 Challenges in treating children and adolescents with antipsychotic agents
, European Neuropsychopharmacology 24: S518-S519 (2014)

P.3.c.009 Effects of antipsychotics on the glutathione and antioxidative enzymes in the brain of rats treated perinatally with phencyclidine
, European Neuropsychopharmacology 24: S519-S520 (2014)

P.3.d.002 Incidence of readmission between short-term electroconvulsive therapy and maintenance electroconvulsive therapy
, European Neuropsychopharmacology 24: S521-S522 (2014)

P.3.d.005 Metabolic syndrome in patients on antipsychotics: about 148 patients
, European Neuropsychopharmacology 24: S523-S524 (2014)

P.3.d.007 Safety and efficacy of adjunct L-triiodothyronine therapy in patients with acute schizophrenia: a randomised study
, European Neuropsychopharmacology 24: S524-S525 (2014)

P.3.d.008 Simultaneous comparison of efficacy and tolerability of second-generation antipsychotics in schizophrenia: a Mixed Treatment Comparison analysis
, European Neuropsychopharmacology 24: S525-S526 (2014)

P.3.d.010 Predictors of 12 month continuation of paliperidone long acting injection treatment for schizophrenia: a naturalistic cohort study
, European Neuropsychopharmacology 24: S526-S527 (2014)

P.3.d.013 Motives for quetiapine discontinuation in real-world clinical setting: a retrospective review
, European Neuropsychopharmacology 24: S528-S529 (2014)

P.3.d.015 Prolactin levels in schizophrenia patients treated with paliperidone switching from risperidone, aripiprazole and olanzapine
, European Neuropsychopharmacology 24: S529-S530 (2014)

P.3.d.017 Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia patients two case reports and discussion
, European Neuropsychopharmacology 24: S530-S531 (2014)

P.3.d.018 Phase 2 clinical trial of Tc-5619, an alpha 7 nicotinic receptor agonist in the treatment of negative and cognitive symptoms in schizophrenia
, European Neuropsychopharmacology 24: S531-S532 (2014)

P.3.d.020 Neurocognition and social cognition in schizophrenia: the impact of antipsychotic therapy
, European Neuropsychopharmacology 24: S532-S533 (2014)

P.3.d.021 Effectiveness of paliperidone in negative symptoms of schizophrenia after six months of treatment
, European Neuropsychopharmacology 24: S533-S534 (2014)

P.3.d.023 Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder
, European Neuropsychopharmacology 24: S534-S535 (2014)

P.3.d.024 Antipsychotic treatment and outcome in first-episode psychosis: a 2-year longitudinal, multicenter, pragmatic study
, European Neuropsychopharmacology 24: S535-S536 (2014)

P.3.d.026 Pharmacogenetics of clozapine response and metabolic side effects: a comprehensive review and meta-analysis
, European Neuropsychopharmacology 24: S536-S537 (2014)

P.3.d.027 Does medication history profile affect treatment response of antagonist and partial agonist at the D2 receptors in schizophrenia?
, European Neuropsychopharmacology 24: S537-S538 (2014)

P.3.d.029 Analyzing the efficacy of second-generation antipsychotic drugs in treatment-resistant schizophrenia: a meta-analysis
, European Neuropsychopharmacology 24: S538-S539 (2014)

P.3.d.031 Audit of patients on paliperidone palmitate in a mental health trust in England
, European Neuropsychopharmacology 24: S539-S540 (2014)

P.3.d.034 Effects of aripiprazole once-monthly on functioning in patients with schizophrenia
, European Neuropsychopharmacology 24: S541-S542 (2014)

P.3.d.037 Effects of aripiprazole once-monthly in patients with schizophrenia switched from oral antipsychotics to aripiprazole once-monthly
, European Neuropsychopharmacology 24: S543-S544 (2014)

P.3.d.040 Previous oral aripiprazole dose (10 or 30 mg/day): effect on the efficacy and tolerability of aripiprazole once-monthly
, European Neuropsychopharmacology 24: S545-S546 (2014)

P.3.d.043 Early responders show greater improvements than early non-responders during the whole long-term treatment of clozapine
, European Neuropsychopharmacology 24: S547-S548 (2014)

P.3.d.045 Aripiprazole in pregnancy: literature review and case series
, European Neuropsychopharmacology 24: S548-S549 (2014)

P.3.d.046 Switching from oral antipsychotics to aripiprazole once-monthly in a naturalistic setting: hospitalisation rates from a mirror study
, European Neuropsychopharmacology 24: S549-S550 (2014)

P.3.d.048 Once-monthly paliperidone palmitate versus daily oral antipsychotics delays adverse real-world consequences of schizophrenia
, European Neuropsychopharmacology 24: S550-S551 (2014)

P.3.d.050 Assessment of personal and social functioning and caregiver burden in schizophrenics treated with paliperidone palmitate long acting injectable, followed up for 1 year
, European Neuropsychopharmacology 24: S551-S552 (2014)

P.3.d.051 Olanzapine long-acting therapy in schizophrenic patients: clinical dimensions and plasma levels
, European Neuropsychopharmacology 24: S552-S553 (2014)

P.3.d.053 Beliefs toward antipsychotic medication in patients with schizophrenia: preliminary results
, European Neuropsychopharmacology 24: S553-S554 (2014)

P.3.d.055 Cognitive rehabilitation in schizophrenic patients with a comorbid addiction to amphetamine and cannabis
, European Neuropsychopharmacology 24: S554-S555 (2014)

P.3.d.057 Analysis of characteristics associated to psychopharmacological prescription among schizophrenic versus schizoaffective disorders
, European Neuropsychopharmacology 24: S555-S556 (2014)

P.3.d.058 Maintenance efficacy of lurasidone compared to high-dose quetiapine Xr in schizophrenia: results from a post-hoc analysis
, European Neuropsychopharmacology 24: S556-S557 (2014)

P.3.d.061 Effect of lurasidone or risperidone on metabolic syndrome status in patients with schizophrenia: a post hoc analysis of a long-term study
, European Neuropsychopharmacology 24: S558-S559 (2014)

P.3.d.063 Lurasidone for maintenance of efficacy in patients with schizophrenia: a double-blind, placebo-controlled, randomised withdrawal study
, European Neuropsychopharmacology 24: S559-S560 (2014)

P.3.d.066 Hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients
, European Neuropsychopharmacology 24: S561-S562 (2014)

P.3.d.068 Varenicline effects on smoking, cognition and psychiatric symptoms in schizophrenia
, European Neuropsychopharmacology 24: S562-S563 (2014)

P.3.e.001 Clozapine alone and in combination with N-acetylcysteine reverses social isolation rearing induced serotonergic metabolism
, European Neuropsychopharmacology 24: S563-S564 (2014)

P.3.e.003 Recurrence risk and protective factors in patients with a first episode of psychosis
, European Neuropsychopharmacology 24: S564-S565 (2014)

P.3.e.004 Abzymes with catalase-like activity of patients with schizophrenia after treatment with haloperidol
, European Neuropsychopharmacology 24: S565-S566 (2014)

P.3.f.002 Sexual dysfunction in outpatients with schizophrenia
, European Neuropsychopharmacology 24: S566-S567 (2014)

P.3.f.004 Remission structure in 10-year course of schizophrenia: a naturalistic study
, European Neuropsychopharmacology 24: S567-S568 (2014)

P.3.f.005 Sexual dysfunction in drug naive psychotic patients treated with antipsychotics
, European Neuropsychopharmacology 24: S568-S569 (2014)

P.3.f.007 Arachnoid cyst in patients with first episode psychosis: three case reports
, European Neuropsychopharmacology 24: S569-S570 (2014)

P.3.f.009 Low disease perception reduces compliance and functioning in schizophrenia in comparison with second pulmonary tuberculosis
, European Neuropsychopharmacology 24: S570-S571 (2014)

P.3.f.010 Some peculiarities in diagnosing delirium in elderly patients in a general hospital by different medical specialists
, European Neuropsychopharmacology 24: S571-S572 (2014)

P.3.f.012 Positive schizotypy associated negative facial emotion recognition and neurocognitive deficits
, European Neuropsychopharmacology 24: S572-S573 (2014)

P.3.f.013 Long-acting second-generation antipsychotics, beyond efficacy: a 12-month prospective study on patients' attitudes towards treatment
, European Neuropsychopharmacology 24: S573-S574 (2014)

P.3.f.015 Expressed emotion in relatives of patients with schizophrenia, bipolar disorder and diabetes: a comparison
, European Neuropsychopharmacology 24: S574-S575 (2014)

P.3.f.018 Metabolic syndrome related cardiovascular disease risk in schizophrenia
, European Neuropsychopharmacology 24: S576-S577 (2014)

P.4.a.002 Role of endocannabinoid signaling in the dorsolateral periaqueductal gray on the modulation of distinct panic-like responses
, European Neuropsychopharmacology 24: S577-S578 (2014)

P.4.a.006 Psychometric properties of the 1-week dimensional anxiety scales for Dsm-5 in a non-clinical student sample
, European Neuropsychopharmacology 24: S579-S580 (2014)

P.4.a.008 Oxytocin controls the Crf gene via Crtc3: implications for stress-related disorders
, European Neuropsychopharmacology 24: S580-S581 (2014)

P.4.a.009 Unc-51-like kinase 4 heterozygous mice display anxiety-like behaviour and alterations in the Gabaergic system within the amygdala
, European Neuropsychopharmacology 24: S581-S582 (2014)

P.4.a.011 Chronic exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses the neuropathy in a diabetic mice model
, European Neuropsychopharmacology 24: S582-S583 (2014)

P.4.a.014 Repeated treatment with an anandamide metabolism inhibitor attenuates long-lasting consequences in a mouse model of post-traumatic stress disorder (Ptsd)
, European Neuropsychopharmacology 24: S584-S585 (2014)

P.4.a.016 Genetic deletion of dopamine D3 receptor accelerates the development of tolerance to the anxiolytic effect of diazepam
, European Neuropsychopharmacology 24: S585-S586 (2014)

P.4.b.001 High anxiety sensitivity is associated with reduced resting heart rate variability
, European Neuropsychopharmacology 24: S587-S588 (2014)

P.4.b.003 Doubt in the insula: risk processing in obsessivecompulsive disorder
, European Neuropsychopharmacology 24: S588-S589 (2014)

P.4.b.006 The role of atypical antipsychotics in obsessivecompulsive disorder resistant to treatment
, European Neuropsychopharmacology 24: S590-S591 (2014)

P.4.b.008 Risperidone augmentation for post-traumatic combat nightmares
, European Neuropsychopharmacology 24: S591-S592 (2014)

P.4.b.012 Efficacy and safety of sertraline treatment of posttraumatic stress disorder
, European Neuropsychopharmacology 24: S593-S594 (2014)

P.4.b.014 Brain-derived neurotrophic factor (Bdnf) as a predictive factor for post-traumatic stress disorder (Ptsd)
, European Neuropsychopharmacology 24: S594-S595 (2014)

P.4.b.015 Separation anxiety and mood symptoms among patients with panic disorder
, European Neuropsychopharmacology 24: S595-S596 (2014)

P.4.b.017 Functional connectivity of basolateral and centromedial amygdala in obsessivecompulsive disorder
, European Neuropsychopharmacology 24: S596-S597 (2014)

P.4.b.020 Time-dependent atomoxetine administration decreases negative conditioned response in a differential fear conditioning paradigm
, European Neuropsychopharmacology 24: S598-S599 (2014)

P.4.b.022 Native Turkish patients and Turkish immigrants: a comparison in terms of clinical features of generalised anxiety disorder
, European Neuropsychopharmacology 24: S599-S600 (2014)

P.4.b.023 An updated meta-analysis of classical fear conditioning in the anxiety disorders
, European Neuropsychopharmacology 24: S600-S601 (2014)

P.4.b.025 Association between symptoms of posttraumatic stress disorder and blood pressure in the elderly
, European Neuropsychopharmacology 24: S601-S602 (2014)

P.4.b.028 Medication therapy in anxiety disorder
, European Neuropsychopharmacology 24: S603-S604 (2014)

P.4.b.030 Impairment in eating habits among 512 earthquake survivors: role of gender and Dsm-5 Ptsd
, European Neuropsychopharmacology 24: S604-S605 (2014)

P.4.c.001 The use of augmentation strategies in treatment resistant anxiety disorders: a meta-analysis and systematic review
, European Neuropsychopharmacology 24: S605-S606 (2014)

P.4.c.002 Behavioural effects of cannabidiol in chronically stressed mice is mediated by neurogenesis and autophagy through Cb1 receptor activation
, European Neuropsychopharmacology 24: S606-S607 (2014)

P.4.c.004 Proteomic analysis of changes in protein expression in hippocampus mitochondria of prenatally stressed rats treated with fluoxetine
, European Neuropsychopharmacology 24: S607-S608 (2014)

P.4.C.005 Effect of flavonoids isolated from Erythrina velutina on oxidative stress in mouse brains
, European Neuropsychopharmacology 24: S608-S609 (2014)

P.4.c.007 Opioid receptors as potential drug targets for controlling fear responses and preventing post-traumatic stress disorder
, European Neuropsychopharmacology 24: S609-S610 (2014)

P.4.C.009 Fluoxetine modulating dorsal and ventral hippocampal Bdnf as responsible for facilitating extinction memory retention
, European Neuropsychopharmacology 24: S610-S611 (2014)

P.4.d.001 Developing fMri markers for individual response prediction in panic disorder with agoraphobia: a machine-learning approach
, European Neuropsychopharmacology 24: S611-S612 (2014)

P.4.d.002 D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessivecompulsive disorders
, European Neuropsychopharmacology 24: S612-S613 (2014)

P.4.d.004 Falls in the elderly: are we using benzodiazepines right?
, European Neuropsychopharmacology 24: S613-S614 (2014)

P.4.d.006 Predictors of therapeutic response in patients with obsessivecompulsive disorder, panic disorder and social phobia
, European Neuropsychopharmacology 24: S614-S615 (2014)

P.4.d.008 Rebound of affective symptoms following acute cessation of deep brain stimulation in obsessivecompulsive disorder
, European Neuropsychopharmacology 24: S615-S616 (2014)

P.4.d.009 From over-awareness to obsessive behaviour error monitoring system dysfunction in patients with obsessivecompulsive disorder
, European Neuropsychopharmacology 24: S616-S617 (2014)

P.4.d.011 Influence of Dat1 and Drd2 gene variants on antidepressant response in generalised anxiety disorder
, European Neuropsychopharmacology 24: S617-S618 (2014)

P.4.e.001 Sub-chronic stress not only induces pro-inflammatory cytokines but also activates Nrlp3 inflammasome in rats
, European Neuropsychopharmacology 24: S618-S619 (2014)

P.4.f.001 The cumulative effect of childhood trauma on adult mental and physical health: results from the Marine Resiliency Study
, European Neuropsychopharmacology 24: S619-S620 (2014)

P.4.f.003 Fast Bdnf serum level increase and association of diurnal Bdnf profile with antidepressant therapy response after sleep deprivation
, European Neuropsychopharmacology 24: S620-S621 (2014)

P.4.f.005 The experience of free will in patients with obsessivecompulsive disorder or Parkinson's disease treated with deep brain stimulation
, European Neuropsychopharmacology 24: S621-S622 (2014)

P.4.f.007 Fatigue and decreased quality of life in early stage thyroid cancer survivors
, European Neuropsychopharmacology 24: S622-S623 (2014)

P.4.f.008 Comparison of neurocognitive performance in patients with early onset and late onset obsessivecompulsive disorder
, European Neuropsychopharmacology 24: S623-S624 (2014)

P.4.f.010 Factors associated with the duration of untreated illness in obsessivecompulsive disorder
, European Neuropsychopharmacology 24: S624-S625 (2014)

P.5.a.002 Association of plasma C-reactive protein levels with mild cognitive impairment and Alzheimer's disease
, European Neuropsychopharmacology 24: S625-S626 (2014)

P.5.a.005 Selol exhibits antioxidative and cytoprotective properties in Pc12 cells by activating glutathione peroxidase
, European Neuropsychopharmacology 24: S627-S628 (2014)

P.5.a.007 Extracellular oligomers of alpha-synuclein induce Parkin modifications and dopaminergic Pc12 cell death
, European Neuropsychopharmacology 24: S628-S629 (2014)

P.5.a.009 Study of biochemical and behavioural changes induced by exogenous adminstration of A1-40 and A1-42 in the hippocampus and amygdala
, European Neuropsychopharmacology 24: S629-S630 (2014)

P.5.a.011 Metal-induced microtubules assembly disturbances
, European Neuropsychopharmacology 24: S631-S632 (2014)

P.5.b.001 Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep
, European Neuropsychopharmacology 24: S632-S633 (2014)

P.5.b.003 Delirium can increase hospital stay
, European Neuropsychopharmacology 24: S633-S634 (2014)

P.5.b.005 The role of the clock drawing test among the diagnostic markers in elderly psychiatric patients
, European Neuropsychopharmacology 24: S634-S635 (2014)

P.5.b.006 Morphological and functional connectivity change of basal ganglia in amnestic mild cognitive impairment
, European Neuropsychopharmacology 24: S635-S636 (2014)

P.5.b.008 Use of acetylcholinesterase inhibitors in routine clinical practice
, European Neuropsychopharmacology 24: S636-S637 (2014)

P.5.b.010 Multistrategic memory training in non-dementic elders
, European Neuropsychopharmacology 24: S637-S638 (2014)

P.5.b.012 A total inspection of cognitive dysfunction in elderly persons of one city
, European Neuropsychopharmacology 24: S638-S639 (2014)

P.5.b.014 Huntington's disease mimicking bipolar disorder: a case report
, European Neuropsychopharmacology 24: S639-S640 (2014)

P.5.c.001 The protective role of Ampk and Akt in neurotoxicity caused by intracellular and extracellular alpha-synuclein accumulation in vitro
, European Neuropsychopharmacology 24: S641-S642 (2014)

P.5.c.003 Involvement of noradrenergic system in Parkinson's disease study on novel transgenic mouse models
, European Neuropsychopharmacology 24: S642-S643 (2014)

P.5.c.004 The influence of hypothalamic proline-rich polypeptide-1 on stem cell maintenance in hippocampus of amyloid-exposed rats
, European Neuropsychopharmacology 24: S643-S644 (2014)

P.5.d.002 Vitamin D deficiency in patients with intellectual disability on carbamazepine
, European Neuropsychopharmacology 24: S644-S645 (2014)

P.5.d.004 Medical marijuana/cannabis treatment of Tourette's syndrome: focus on the quality of life
, European Neuropsychopharmacology 24: S645-S646 (2014)

P.5.d.005 Role of cannabinoid Cb2 receptor in Parkinson's disease
, European Neuropsychopharmacology 24: S646-S647 (2014)

P.5.e.002 The importance of brainstem auditory evoked response in dogs with congenital hydrocephalus
, European Neuropsychopharmacology 24: S647-S648 (2014)

P.5.f.002 Psychometric properties of the mini-mental state examination Korean version
, European Neuropsychopharmacology 24: S648-S649 (2014)

P.5.f.003 Relationship between psychotic symptoms of delirium and clinical outcomes
, European Neuropsychopharmacology 24: S649-S650 (2014)

P.5.f.005 Acute tryptophan depletion modulates kynurenine production: a challenging component of cognitive impairment in braingut axis disorders
, European Neuropsychopharmacology 24: S650-S651 (2014)

P.5.f.010 Evaluation of the treatment of elderly agitated patients:a preliminary study
, European Neuropsychopharmacology 24: S652-S653 (2014)

P.6.a.002 Dna damages and behaviour disorders in pups of rats exposed to alcohol in the antenatal period, and its correction by afobazole
, European Neuropsychopharmacology 24: S653-S654 (2014)

P.6.a.004 Gender differences of alcohol dependence in Russia and in Germany
, European Neuropsychopharmacology 24: S654-S655 (2014)

P.6.a.006 How alcohol intake affects on time-based expectancies
, European Neuropsychopharmacology 24: S655-S656 (2014)

P.6.a.009 Increased ethanol self-administration associated with synaptic plasticity alterations induced by early life stress in mice
, European Neuropsychopharmacology 24: S657-S658 (2014)

P.6.a.011 Role of C1473G polymorphism in mouse tryptophan hydroxylase 2 gene in ethanol treatment effect on behaviour and brain serotonin system
, European Neuropsychopharmacology 24: S658-S659 (2014)

P.6.a.012 Social defeat in adolescent mice increased the vulnerability for alcohol consumption
, European Neuropsychopharmacology 24: S659-S660 (2014)

P.6.a.014 Chronic ethanol consumption in C57Bl/6J mice induces Bdnf epigenetic and signaling alterations, and cognitive deficits
, European Neuropsychopharmacology 24: S660-S661 (2014)

P.6.a.017 Chronic ethanol exposure increases inducible nitric oxide synthase expression in the dorsolateral periaqueductal gray matter of rats
, European Neuropsychopharmacology 24: S662-S663 (2014)

P.6.b.001 A double-blind placebo-controlled randomised trial of pregabalin for alcohol dependence: interim analysis
, European Neuropsychopharmacology 24: S663-S664 (2014)

P.6.b.004 Disgust counterconditioning during reconsolidation reduces liking of and abolishes attentional bias to alcohol cues
, European Neuropsychopharmacology 24: S665-S666 (2014)

P.6.b.006 Carnosine protects blood plasma proteins from damaging effect of acetaldehyde
, European Neuropsychopharmacology 24: S666-S667 (2014)

P.6.b.008 Temperaments and characters associated with the relapse in alcohol-dependent patients
, European Neuropsychopharmacology 24: S667-S668 (2014)

P.6.b.009 High-risk alcohol relapse scale is a good instrument for predicting long-term abstinence after an episode of alcoholic hepatitis
, European Neuropsychopharmacology 24: S668-S669 (2014)

P.6.b.011 Nalmefene in dual diagnosed alcoholics: an open study
, European Neuropsychopharmacology 24: S669-S670 (2014)

P.6.b.013 Alcohol, coffee and energy drink consumption patterns in a sample of Italian adolescents and young adults
, European Neuropsychopharmacology 24: S670-S671 (2014)

P.6.b.016 Effect of nalmefene as needed on alcohol consumption and mood in alcohol dependent patients with comorbid mood disorder
, European Neuropsychopharmacology 24: S672-S673 (2014)

P.6.b.018 Reflection impulsivity in binge drinking: behavioural and volumetric correlates
, European Neuropsychopharmacology 24: S673-S674 (2014)

P.6.c.002 Blockade of central serotonin 2B receptors reduces cocaine-induced hyperlocomotion independently of subcortical Da outflow
, European Neuropsychopharmacology 24: S675-S676 (2014)

P.6.c.004 New peptide-origin anxiolytics, Gb-115 and Selank, as possible tools in treatment of opiate addiction: an experimental study
, European Neuropsychopharmacology 24: S676-S677 (2014)

P.6.c.007 The role of adenosine receptors in the nucleus accumbens during morphine withdrawal
, European Neuropsychopharmacology 24: S678-S679 (2014)

P.6.c.009 The role of ras guanine nucleotide-releasing factor 1 (ras-Grf1) in cocaine self-administration
, European Neuropsychopharmacology 24: S679-S680 (2014)

P.6.c.012 Immediate and persisting effect of toluene chronic inhalation on behaviour in maze and on hippocampal structure in adult and adolescent rats
, European Neuropsychopharmacology 24: S681-S682 (2014)

P.6.c.014 Acute and chronic effects of Mdma on hippocampal cell fate markers in adolescent and adult rats
, European Neuropsychopharmacology 24: S682-S683 (2014)

P.6.c.016 Dynamic epigenetic landscapes define progression to cocaine addiction
, European Neuropsychopharmacology 24: S683-S684 (2014)

P.6.c.019 Persistent microglia activation contributes to the depressive/psychotic-like phenotype induced by adolescent Thc exposure in rats
, European Neuropsychopharmacology 24: S685-S686 (2014)

P.6.d.001 Prevalence of cognitive impairments and emotional recognition bias in substance abuse or dependence currently in remission
, European Neuropsychopharmacology 24: S686-S687 (2014)

P.6.d.002 Is internet addiction prevalent among methadone maintenance treatment (Mmt) patients? Data from Las Vegas and Tel Aviv
, European Neuropsychopharmacology 24: S687-S688 (2014)

P.6.d.004 Response to methadone maintenance treatment: what is the role of personality?
, European Neuropsychopharmacology 24: S688-S689 (2014)

P.6.d.005 The impact of oral and implantable formulations of naltrexone on overall functioning and social adjustment in opioid dependent patients
, European Neuropsychopharmacology 24: S689-S690 (2014)

P.6.d.008 Novel psychoactive substances as new frontiers of polyabuse: the case of Camfetamine
, European Neuropsychopharmacology 24: S690-S691 (2014)

P.6.d.010 Neural correlates of cue-induced craving for amphetamine
, European Neuropsychopharmacology 24: S691-S692 (2014)

P.6.d.013 Assessment of early psychiatric symptoms among substance users: a preliminary study
, European Neuropsychopharmacology 24: S693-S694 (2014)

P.6.d.015 Opioid consumers: from the pain clinic to the addictive behaviours unit
, European Neuropsychopharmacology 24: S694-S695 (2014)

P.6.d.016 Neuropsychological and educational outcomes related to adolescent cannabis use, a prospective cohort study
, European Neuropsychopharmacology 24: S695-S696 (2014)

P.6.d.018 Effects of delta-9-tetrahydrocannabinol and cannabidiol on estimated cannabis potency and actual titration
, European Neuropsychopharmacology 24: S696-S697 (2014)

P.6.e.002 Prenatal methamphetamine exposition and and age-related changes in the expression of Nmda receptor subunits in rats
, European Neuropsychopharmacology 24: S697-S698 (2014)

P.6.e.003 Experimental evidence on the increase of glutamic acid brain levels, induced by repeated ingestion of dietary monosodium glutamate
, European Neuropsychopharmacology 24: S698-S699 (2014)

P.6.f.002 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [11C]carfentanil Pet study
, European Neuropsychopharmacology 24: S699-S700 (2014)

P.6.f.003 Increase in Ptsd but not depression symptoms is associated with increases in alcohol and cigarette consumption after military deployment
, European Neuropsychopharmacology 24: S700-S701 (2014)

P.6.f.005 Internet addiction disorder in a sample of students
, European Neuropsychopharmacology 24: S701-S702 (2014)

P.6.f.007 Compulsivity in binge-eating disorder
, European Neuropsychopharmacology 24: S702-S703 (2014)

P.6.f.008 Does genetics predict severity of gambling disorder? A preliminary study on an Italian sample of gamblers
, European Neuropsychopharmacology 24: S703-S704 (2014)

P.7.a.002 Anti--melanocyte-stimulating hormone autoantibodies in patients with eating disorders and melanocortin 4 receptor signaling
, European Neuropsychopharmacology 24: S704-S705 (2014)

P.7.b.001 Cortisol response to stress in adults with attention deficit hyperactivity disorder
, European Neuropsychopharmacology 24: S705-S706 (2014)

P.7.b.005 Hyperfocusing as a dimension of adult Adhd
, European Neuropsychopharmacology 24: S707-S708 (2014)

P.7.b.006 The psychopathology and quality of life in children and adolescents with precocious puberty
, European Neuropsychopharmacology 24: S708-S709 (2014)

P.7.b.008 Auditory verbal hallucinations in youth: a longitudinal observational study
, European Neuropsychopharmacology 24: S709-S710 (2014)

P.7.b.009 Predictors of weight gain after six months of treatment with second-generation antipsychotics in pediatric and adult patients
, European Neuropsychopharmacology 24: S710-S711 (2014)

P.7.b.011 Validation of the Weiss Functional Impairment Rating Scale Parent Report Form in attention deficit/hyperactivity disorder
, European Neuropsychopharmacology 24: S711-S712 (2014)

P.7.b.012 Testosterone and explosive aggression in children with autism spectrum disorders
, European Neuropsychopharmacology 24: S712-S713 (2014)

P.7.b.015 Neurophysiological alterations in adults with attention deficit/hyperactivity disorder: an event-related potential study
, European Neuropsychopharmacology 24: S714-S715 (2014)

P.7.b.017 Premorbid to post-morbid functional adjustment course in adolescents after a first episode psychosis
, European Neuropsychopharmacology 24: S715-S716 (2014)

P.7.b.018 Maternal depression symptoms, unhealthy diet and child emotionalbehavioural dysregulation
, European Neuropsychopharmacology 24: S716-S717 (2014)

P.7.c.001 The use of medication against attention deficit/hyperactivity disorder in Slovenia: a drug consumption study
, European Neuropsychopharmacology 24: S717-S718 (2014)

P.7.C.003 Effects of methylphenidate on dopamine targets in the left and right brain hemispheres
, European Neuropsychopharmacology 24: S718-S719 (2014)

P.7.C.004 Voluntary chronic methylphenidate oral intake in rats, effect on ventral tegmental area dopamine neurons
, European Neuropsychopharmacology 24: S719-S720 (2014)

P.7.d.002 Effects of risperidone in the treatment of conduct disorder in children without intellectual disability
, European Neuropsychopharmacology 24: S720-S721 (2014)

P.7.d.004 Divalproex sodium and risperidone in the treatment of cognitive, behavioral and social dysfunction in preschool children with Pdd and Adhd
, European Neuropsychopharmacology 24: S721-S722 (2014)

P.7.d.005 Cytochromes Cyp2D6 and Cyp2C9 and relapse depression rates in a cohort of adolescents
, European Neuropsychopharmacology 24: S722-S723 (2014)

P.7.d.007 Review of atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in patients with common comorbidities
, European Neuropsychopharmacology 24: S723-S724 (2014)

P.7.d.008 Characteristics of readmitted Adhd children who had non-adherence to medication before
, European Neuropsychopharmacology 24: S724-S725 (2014)

P.7.d.010 Face and emotion recognition in children with Adhd and autism spectrum disorders: effects of methylphenidate
, European Neuropsychopharmacology 24: S725-S726 (2014)

P.7.d.013 Guanfacine extended release for attention-deficit/hyperactivity disorder following inadequate response to prior methylphenidate
, European Neuropsychopharmacology 24: S727-S728 (2014)

P.7.e.001 Opposite effects of acute methylphenidate administration in children versus adult Adhd patients during emotional processing
, European Neuropsychopharmacology 24: S728-S729 (2014)

P.7.f.002 The affective dimension of early-onset first episode of psychosis
, European Neuropsychopharmacology 24: S729-S730 (2014)

P.7.f.003 Mental disorders in children with Hiv/Aids
, European Neuropsychopharmacology 24: S730-S731 (2014)

P.7.f.005 The impact of specific behavioral problems on the health-related quality of life of children and adolescents with epilepsy
, European Neuropsychopharmacology 24: S731-S732 (2014)

P.7.f.007 Abuse of psychotropic drugs among Serbian adolescents
, European Neuropsychopharmacology 24: S732-S733 (2014)

P.7.f.009 Lisdexamfetamine dimesylate: hydrolysis, pharmacokinetics and duration of therapeutic action in children and adolescents with Adhd
, European Neuropsychopharmacology 24: S733-S734 (2014)

P.8.b.001 Secondary prevention in depression, bipolar and addiction via mobile phone
, European Neuropsychopharmacology 24: S734-S735 (2014)

P.8.b.003 Pharmacotherapy review as a safety and cost tool in patients management in Slovenian Psychiatric Hospital
, European Neuropsychopharmacology 24: S735-S736 (2014)

P.8.b.005 Excessive sweating induced by interaction between agomelatine and duloxetine: a cooperation with clinical pharmacist
, European Neuropsychopharmacology 24: S736-S737 (2014)

P.8.b.006 Side effects of zolpidem and temazepam in treating primary insomnia
, European Neuropsychopharmacology 24: S737-S738 (2014)

P.8.b.008 Self-stigmatisation and adherence to treatment
, European Neuropsychopharmacology 24: S738-S739 (2014)

P.8.b.010 Relationships between plasma testosterone and suicidal behaviour in antisocial personality disorder
, European Neuropsychopharmacology 24: S739-S740 (2014)

P.8.b.013 Therapeutic efficacy of generic drugs versus branded antipsychotics and antidepressants: comparative results
, European Neuropsychopharmacology 24: S740-S741 (2014)

P.8.b.014 Magnesium supply improves adherence to hypocaloric diets in women: effects on weight control competence preliminary results
, European Neuropsychopharmacology 24: S741-S742 (2014)

P.8.b.019 Prevalence of anti-glutamic acid decarboxylase (anti-Gad) antibodies in psychiatric patients
, European Neuropsychopharmacology 24: S744-S745 (2014)

P.8.b.021 Respiratory improvement in chronic asthma treated with autogenic therapy
, European Neuropsychopharmacology 24: S745-S746 (2014)

P.8.b.023 Overlapping and distinct sex-specific serum molecular profiles in schizophrenia, depression, bipolar disorder, and Asperger syndrome
, European Neuropsychopharmacology 24: S746-S747 (2014)

P.8.b.026 Pharmacokinetics predictive of risperidone in man with clinical implications
, European Neuropsychopharmacology 24: S748-S749 (2014)

C.02.01 Efficacy and tolerability of antipsychotic treatment
, European Neuropsychopharmacology 24: S752-S753 (2014)

C.04.03 Clinical management of mania with depressive symptoms
, European Neuropsychopharmacology 24: S755-S756 (2014)

C.07.02 Agitation continuum as critical symptom in psychiatric emergencies
, European Neuropsychopharmacology 24: S756-S757 (2014)

C.08.02 Are psychotic events neurotoxic?
, European Neuropsychopharmacology 24: S757-S758 (2014)

C.09.01 Complicating factors in the diagnosis and treatment of depression
, European Neuropsychopharmacology 24: S758-S759 (2014)

C.10.03 Clinical evidence with opioid modulators in alcohol dependence
, European Neuropsychopharmacology 24: S760-S761 (2014)

C.11.02 Balancing antipsychotic efficacy with minimal metabolic burden: new developments in schizophrenia management
, European Neuropsychopharmacology 24: S761-S762 (2014)

C.12.01 The nature of relapse in schizophrenia
, European Neuropsychopharmacology 24: S762-S763 (2014)

S.01.03 Neurobiology of adult separation anxiety disorder
, European Neuropsychopharmacology 25: S111-S112 (2015)

S.02.04 Digital biomarkers for mood disorders
, European Neuropsychopharmacology 25: S112-S113 (2015)

S.03.03 Cue-induced brain activation and its association with automated and obsessive-compulsive alcohol consumption
, European Neuropsychopharmacology 25: S113-S114 (2015)

S.04.04 Clinical and brain structural correlates of Ncam and polysialic acid serum levels in schizophrenia
, European Neuropsychopharmacology 25: S115-S116 (2015)

S.05.02 Efficacy and cognitive side effects of ultrabrief pulse electroconvulsive therapy (Ntr1304)
, European Neuropsychopharmacology 25: S116-S117 (2015 )

S.06.03 Neurobiological risk factors for schizophrenia in adults with 22q11.2Ds
, European Neuropsychopharmacology 25: S118-S119 (2015)

S.07.04 Neuroimmunological regulators of compulsivity
, European Neuropsychopharmacology 25: S120-S121 (2015)

S.08.03 Gene and microRna expression in the mode of action of treatments for major depression
, European Neuropsychopharmacology 25: S121-S122 (2015)

S.09.01 Pharmacological treatment of frontal lobe dementia: recent advances
, European Neuropsychopharmacology 25: S122-S123 (2015)

S.10.02 Experimental medicine with phMri: study designs
, European Neuropsychopharmacology 25: S124-S125 (2015)

S.11.01 Gene-environment interaction and prefrontal cortical function as measured by fMri
, European Neuropsychopharmacology 25: S125-S126 (2015)

S.11.04 Are endophenotypes a useful concept?
, European Neuropsychopharmacology 25: S126-S127 (2015)

S.12.03 Modulation of glutamatergic transmission in the infralimbic cortex evokes antidepressant-like effects in rats
, European Neuropsychopharmacology 25: S127-S128 (2015)

S.12.05 Allosteric modulation of Nmda receptors rescues impaired synaptic plasticity in experimental Parkinsonism
, European Neuropsychopharmacology 25: S128-S129 (2015)

S.13.03 Rct administering oxytocin for schizophrenia, a three week add-on study
, European Neuropsychopharmacology 25: S130-S131 (2015)

S.14.02 Dopaminergic function, choice impulsivity and cocaine use in cocaine-dependent humans
, European Neuropsychopharmacology 25: S131-S132 (2015)

S.14.04 How a stick becomes a reward to reinforce compulsivity in Ocd: implications for addiction
, European Neuropsychopharmacology 25: S132-S133 (2015)

S.16.04 Sleep-related neuroplasticity in major depression
, European Neuropsychopharmacology 25: S136-S137 (2015)

S.18.03 Machine learning as a tool to assist in diagnosis
, European Neuropsychopharmacology 25: S138-S139 (2015)

S.19.02 Structural and functional imaging effects of Cnvs in mouse and man
, European Neuropsychopharmacology 25: S139-S140 (2015)

S.20.01 The microbiome-gut-brain axis: how bacteria can cause mood and psychotic disorders
, European Neuropsychopharmacology 25: S140-S141 (2015)

S.21.02 How to rescue Cns active drugs which fail in one indication: experience from the Ecnp Medicines Chest Initiative
, European Neuropsychopharmacology 25: S141-S142 (2015)

S.23.03 Genetic and epigenetic moderator of the first transcriptome response to stress: importance for stress-related psychiatric disorders?
, European Neuropsychopharmacology 25: S144-S145 (2015)

S.24.01 mTor controls structural plasticity of dopaminergic neurons: implication in the actions of ketamine
, European Neuropsychopharmacology 25: S145-S146 (2015)

S.26.02 Genomics research in suicidology
, European Neuropsychopharmacology 25: S148-S149 (2015)

S.27.01 Novel developments in machine learning techniques for neuroimaging
, European Neuropsychopharmacology 25: S149-S150 (2015)

S.28.02 Role of kynurenine and glutamate in inflammation-induced depression
, European Neuropsychopharmacology 25: S150-S151 (2015)

E.03.01 Irritability and Dsm-5 disruptive mood dysregulation disorder: correlates, predictors, and outcome in children
, European Neuropsychopharmacology 25: S153-S154 (2015)

P.1.a.002 Genetics of long-term treatment outcome in bipolar disorder
, European Neuropsychopharmacology 25: S159-S160 (2015)

P.1.a.003 Genetic polymorphisms of chimerin-1 in schizophrenia and ischemic stroke
, European Neuropsychopharmacology 25: S160-S161 (2015)

P.1.a.005 Effects of atypical antipsychotics on emotional memory and locomotion: altered gene expression levels of Bdnf and Creb in the hippocampus of mice
, European Neuropsychopharmacology 25: S161-S162 (2015)

P.1.a.007 Four polymorphisms of Slc6A4 are novel predictors of Ssri/Snri response in depressive disorder: sequencing analysis of Slc6A4
, European Neuropsychopharmacology 25: S162-S163 (2015)

P.1.a.008 Oxytocin receptor gene hypomethylation as a potential risk factor in social anxiety?
, European Neuropsychopharmacology 25: S163-S164 (2015)

P1.a.011 Association of Ahi1 polymorphisms with the diagnosis and treatment outcome of schizophrenia
, European Neuropsychopharmacology 25: S164-S165 (2015)

P1.a.013 Effect of Htr7 gene variants on the efficacy of second-generation antipsychotics with 5-Ht7R antagonism in Japanese schizophrenia patients
, European Neuropsychopharmacology 25: S165-S166 (2015)

P.1.a.014 Allelic variation in corticotropin-releasing hormone receptor 1 changes receptor activity by alternative splicing
, European Neuropsychopharmacology 25: S166-S167 (2015)

P.1.a.016 Investigating schizophrenia genome-wide association studies risk variants in cognitive and neuroimaging defects in the Genus Consortium collection
, European Neuropsychopharmacology 25: S167-S168 (2015)

P.1.a.021 Genetic and epigenetic regulation of cannabinoid receptor type-1 in obesity
, European Neuropsychopharmacology 25: S169-S170 (2015)

P1.a.023 Impact of a Snp in Sigmar1 on major depression, bipolar disorder and treatment response
, European Neuropsychopharmacology 25: S170-S171 (2015)

P.1.a.024 Deoxyribonucleic acid methylation marks of psychotropic drug use in bipolar disorder patients; an explorative pilot study
, European Neuropsychopharmacology 25: S171-S172 (2015)

P.1.a.027 Association between the polymorphism of 5-Httlpr gene and affective temperament dimensions using the Temps-A scale in obesity
, European Neuropsychopharmacology 25: S172-S173 (2015)

P1.a.029 Early-life trauma as susceptibility to develop depression in hepatitis C virus patients following long-term treatment with interferon-alpha
, European Neuropsychopharmacology 25: S173-S174 (2015)

P.1.a.031 Lifetime stress accelerates epigenetic aging
, European Neuropsychopharmacology 25: S174-S175 (2015)

P.1.a.034 Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease: a systematic review
, European Neuropsychopharmacology 25: S175-S176 ( 2015)

P.1.a.037 Compulsive behaviour in adolescent patients with anorexia nervosa
, European Neuropsychopharmacology 25: S177-S178 (2015)

P.1.b.002 The Eeg specificity in children with attention deficit hyperactivity disorder (Adhd)
, European Neuropsychopharmacology 25: S178-S179 (2015)

P.1.b.004 Chronic supplementation with thiamine enhances the anticonvulsant effect of diazepam on pentylenetetrazole induced seizure in mice
, European Neuropsychopharmacology 25: S179-S180 (2015)

P.1.b.005 On the balance and distribution of adenosine A2A homoreceptor and A1-A2A isoreceptor complexes in the hippocampus of the rat brain
, European Neuropsychopharmacology 25: S180-S181 (2015)

P.1.b.007 Idiopathic acute polyradiculoneuritis concurrent with acquired myasthenia gravis or a separate entity in a West Highland White Terrier dog?
, European Neuropsychopharmacology 25: S181-S182 (2015)

P.1.b.009 Suicide attempts are associated with hippocampal volumes in depressed patients, independently from previous antidepressant treatments
, European Neuropsychopharmacology 25: S182-S183 (2015)

P.1.b.011 The effect of a combination of D-cycloserine treatment and extinction therapy on M1 protein expression in rats traumatised with cat odor
, European Neuropsychopharmacology 25: S183-S184 (2015)

P.1.b.013 Opioid and dopamine transmission in chronic pain and health are diametrically opposed: a phMri study
, European Neuropsychopharmacology 25: S184-S185 (2015)

P.1.b.014 Agenesis of corpus callosum: incidental finding in a schizophrenic patient a case report
, European Neuropsychopharmacology 25: S185-S186 (2015)

P.1.b.016 Differential features of allodynia associated with cephalic versus extra-cephalic neuropathic pain in rats
, European Neuropsychopharmacology 25: S186-S187 (2015)

P.1.b.017 Effects of zinc treatment on the 5-Ht1A receptor function: behavioural responses
, European Neuropsychopharmacology 25: S187-S188 (2015)

P.1.b.019 Effects of antipsychotic treatment on the proteins of glutamatergic synapse in the brain of rats perinatally treated with phencyclidine
, European Neuropsychopharmacology 25: S188-S189 (2015)

P.1.b.022 Integration and segregation of default mode network resting-state functional connectivity in high-functioning autism spectrum disorder
, European Neuropsychopharmacology 25: S190-S191 (2015)

P.1.b.024 Altered structural plasticity in acute and remitted depressive patients investigated with ultra-high field magnetic resonance imaging
, European Neuropsychopharmacology 25: S191-S192 (2015)

P.1.b.026 Abnormalities in the auditory and frontal cortices in a mouse model of 22q11.2 Deletion Syndrome
, European Neuropsychopharmacology 25: S192-S193 (2015)

P.1.b.029 Neurobiological correlates of aberrant motor functioning in schizophrenia
, European Neuropsychopharmacology 25: S193-S194 (2015)

P.1.b.031 The adenosine 1 receptor modulates basal synaptic activity in the pre-frontal cortex
, European Neuropsychopharmacology 25: S194-S195 (2015)

P.1.b.032 Effectiveness of the combination of Ect and pharmacological drugs in patients with different diagnosis and description of the incidences observed
, European Neuropsychopharmacology 25: S195-S196 (2015)

P.1.c.006 MiRnas peripheral signature associated with childhood trauma exposure
, European Neuropsychopharmacology 25: S196-S197 (2015)

P.1.c.007 Prenatal influences facilitate the precipitation of a schizophrenia-like phenotype: assessing the role of the endocannabinoid system
, European Neuropsychopharmacology 25: S197-S198 (2015)

P.1.c.010 Access to diagnosis, treatment and supportive services: results from the caregiver perspective on pediatric Adhd study in Europe
, European Neuropsychopharmacology 25: S199-S200 (2015)

P.1.c.012 Open-label study comparing the efficacy and tolerability of aripiprazole and risperidone in the treatment of children with autism spectrum disorder and Adhd
, European Neuropsychopharmacology 25: S200-S201 (2015)

P.1.c.013 Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children with Adhd: A new electrocardiographic T-waves marker
, European Neuropsychopharmacology 25: S201-S202 (2015)

P.1.C.016 Perceived social status mobility relates to perigenual anterior cingulate morphology in individuals with ethnic minority status
, European Neuropsychopharmacology 25: S203-S204 (2015)

P.1.C.019 Influences of sex and estrous cycle on behavioural and neurochemical alterations induced by the neonatal administration of ketamine to rats
, European Neuropsychopharmacology 25: S205-S206 (2015)

P.1.d.002 A role for glial-associated kynurenine pathway activation in modulating neuronal outgrowth and complexity
, European Neuropsychopharmacology 25: S206-S207 (2015)

P.1.d.003 Alterations of oligodendroglial cells in the rat brain in phencyclidine animal model of schizophrenia: effects of antipsychotic treatment
, European Neuropsychopharmacology 25: S207-S208 (2015)

P.1.d.005 Glial plasticity as a key mechanism underlying the pathophysiology of depression
, European Neuropsychopharmacology 25: S208-S209 (2015)

P1.e.002 Activation of the brain serotonergic system decreases the expression and activity of liver cytochrome P450 isoforms Cyp1A, 2C11 and 3A
, European Neuropsychopharmacology 25: S209-S210 (2015)

P.1.e.003 Evaluation of cognitive function and brain-derived neurotrophic factor (Bdnf) levels in a sample of euthymic bipolar patients
, European Neuropsychopharmacology 25: S210-S211 (2015)

P.1.e.005 Repeated stress hormone measurements after a social stressor in major depressive disorder: association patterns and predictive ability
, European Neuropsychopharmacology 25: S211-S212 (2015)

P.1.e.008 Cortisol and postpartum mental health
, European Neuropsychopharmacology 25: S213-S214 (2015)

P.1.e.009 Neurocognitive and neurochemical responses in patients with anxiety and allostatic load: beyond anxiolysis, can cognition be improved by alprazolam?
, European Neuropsychopharmacology 25: S214-S215 (2015)

P.1.e.012 Relationship between the level of hormones and cognitive abilities of male schizophrenia patients preliminary results
, European Neuropsychopharmacology 25: S215-S216 (2015)

P.1.e.015 Neuronal plasticity of language-related brain regions induced by long-term testosterone treatment
, European Neuropsychopharmacology 25: S217-S218 (2015)

P.1.e.017 A decrease in phosphorylation of Creb may explain delayed place learning and attenuated long-term potentiation in adult-onset hyperthyroidism
, European Neuropsychopharmacology 25: S218-S219 (2015)

P.1.e.018 Maternal l-thyroxine treatment during lactation affects learning and anxiety-like behaviours but not spatial memory in adult rat progeny
, European Neuropsychopharmacology 25: S219-S220 (2015)

P.1.e.022 The influence of cross-sex hormone therapy in transgender persons on neural correlates of empathy
, European Neuropsychopharmacology 25: S221-S222 (2015)

P.1.e.023 Functional mutations in Cadps identified in patients with early-onset bipolar disorder
, European Neuropsychopharmacology 25: S222-S223 (2015)

P.1.e.025 Alterations of serum brain-derived neurotrophic factor levels and its effects on cognitive functions during early and late alcohol withdrawal
, European Neuropsychopharmacology 25: S223-S224 (2015)

P.1.e.026 Relationship between dehydroepiandrosterone sulfate (Dhea-s) levels and severity in patients with major depressive disorder
, European Neuropsychopharmacology 25: S224-S225 (2015)

P.1.f.002 Caffeine affects cytokine secretion after immunity stimulation by Freund's complete adjuvant
, European Neuropsychopharmacology 25: S225-S226 (2015)

P.1.f.004 The effect of acute ketamine administration on Nlrp3 inflammasome activation in a sub-chronic stress model of rats
, European Neuropsychopharmacology 25: S226-S227 (2015)

P.1.f.005 Cytokines and mood in healthy young adults
, European Neuropsychopharmacology 25: S227-S228 (2015)

P.1.f.007 Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease
, European Neuropsychopharmacology 25: S228-S229 (2015)

P.1.f.009 Morningness and eveningness type in patients with multiple sclerosis and relation with clinical severity
, European Neuropsychopharmacology 25: S229-S230 (2015)

P.1.f.010 Is tumor necrosis factor-alpha a sensitive marker of acute exacerbation of severe mental illnesses?
, European Neuropsychopharmacology 25: S230-S231 (2015)

P.1.f.012 Association of psychiatric disorders and diseases affecting the immune system
, European Neuropsychopharmacology 25: S231-S232 (2015)

P.1.f.013 Serum soluble urokinase-type plasminogen activator receptor (suPar) levels in male patients with acute exacerbation of schizophrenia
, European Neuropsychopharmacology 25: S232-S233 (2015)

P.1.f.015 Evidence for central molecular changes and changes to neuronal activity in an animal model of inflammatory bowel disease
, European Neuropsychopharmacology 25: S233-S234 (2015)

P.1.f.019 Methodological aspects of translocator protein positron emission tomography for microglial activation in schizophrenia patients
, European Neuropsychopharmacology 25: S234-S235 (2015)

P.1.f.020 Association between peripheral interleukin 6 and brain response to positive stimuli in a depressive spectrum
, European Neuropsychopharmacology 25: S235-S236 (2015)

P.1.f.022 Nlrp3-inflammasome complex is implicated in depressive behaviour induced by stress
, European Neuropsychopharmacology 25: S236-S237 (2015)

P.1.f.023 Increased prolyl endopeptidase induces alterations in the expression of neural cell adhesion molecule in Sh-Sy5Y neuroblastoma cells
, European Neuropsychopharmacology 25: S237-S238 (2015)

P.1.g.002 Anticonvulsant screening of novel calixarene derivatives containing gamma-aminobutyric acid moieties
, European Neuropsychopharmacology 25: S238-S239 (2015 )

P.1.g.005 Long term ghrelin agonist treatment in mice does not increase weight but reduces fat mass in specific anatomical regions
, European Neuropsychopharmacology 25: S240-S241 (2015)

P.1.g.007 Effect of chronic etanercept (a Tnf- inhibitor) treatment on depressive-like behaviour in aged rats
, European Neuropsychopharmacology 25: S241-S242 (2015)

P.1.g.009 Dissociable effects of mGluR5 modulation on motor and choice impulsivity in rats: interaction with Nmda receptor antagonism
, European Neuropsychopharmacology 25: S242-S243 (2015)

P.1.g.011 Antinociceptive effects of ketamine and alpha-lipoic acid in rats with neuropathic pain
, European Neuropsychopharmacology 25: S243-S244 (2015)

P.1.g.013 Identification of novel bioactives on the alpha-7-nAchR using an at-line cellular bioassay after nanofractionation
, European Neuropsychopharmacology 25: S244-S245 (2015)

P.1.g.014 Intracellular signaling pathways implicated in the antidepressant-like effect of ursolic acid in the tail suspension test
, European Neuropsychopharmacology 25: S245-S246 (2015)

P.1.g.016 Why direct intracerebroventricular injection of 3,4-methylenedioxymethamphetamine (ecstasy) failed to produce serotonin syndrome in animal models?
, European Neuropsychopharmacology 25: S246-S247 (2015)

P.1.g.018 Study of the effects of serotonin 1B/1D selective agonists eletriptan and rizatriptan on pain reactions
, European Neuropsychopharmacology 25: S247-S248 (2015)

P.1.g.019 Antidepressant- and anxiolytic-like properties of S 47445, a novel positive allosteric modulator of Ampa type glutamate receptors
, European Neuropsychopharmacology 25: S248-S249 (2015)

P1.g.023 Atomoxetine for hoarding disorder: a preclinical and clinical investigation
, European Neuropsychopharmacology 25: S249-S250 (2015)

P.1.g.024 Effects of antipsychotic treatment on obsessive-compulsive symptoms in schizophrenia
, European Neuropsychopharmacology 25: S250-S251 (2015)

P.1.g.026 Efficient strategy for obtaining reliable pharmacokinetic parameters in population compartmental approaches
, European Neuropsychopharmacology 25: S251-S252 (2015)

P.1.g.028 Attention deficit and hyperactivity disorder the pharmacological approach in our clinic
, European Neuropsychopharmacology 25: S252-S253 (2015)

P1.g.033 C-terminal fragment of arginine-vasopressin contributes more to the rate of memory trace formation, while its analog improves maintenance of the trace
, European Neuropsychopharmacology 25: S254-S255 (2015)

P.1.g.035 Caenorhabditis elegans as a model of obesity caused by antipsychotics
, European Neuropsychopharmacology 25: S255-S256 (2015)

P.1.g.037 Clinical factors related with treatment adherence in psychotic patients with psychiatric hospitalisation experience
, European Neuropsychopharmacology 25: S256-S257 (2015)

P.1.g.039 Comparison between systemic and central administration of methylene blue and nitroglycerin on orofacial nociceptive behavior in mice
, European Neuropsychopharmacology 25: S257-S258 (2015)

P.1.g.040 2C-selective antagonism with Orm10921 decreases behavioural despair and improves cognition in the Flinders sensitive line rat model of depression
, European Neuropsychopharmacology 25: S258-S259 (2015)

P.1.g.044 Dimeric dipeptide mimetics of the Bdnf loop 4 and loop 1 activate TrkB with different patterns of intracellular signal transduction
, European Neuropsychopharmacology 25: S260-S261 (2015)

P.1.g.045 Functional interaction between serotonin 2A and metabotropic glutamate 2 receptors in the regulation of dopamine release in mouse prefrontal cortex
, European Neuropsychopharmacology 25: S261-S262 (2015)

P.1.g.047 Biological profiling of antidepressant response in depression: associations with neuroinflammation, fatty acid metabolism, and amygdala-reactivity
, European Neuropsychopharmacology 25: S262-S263 (2015)

P.1.g.048 Blockade of Cb1 cannabinoid receptors and activation of Cb2 interact to prevent cocaine-responses
, European Neuropsychopharmacology 25: S263-S264 (2015)

P.1.g.052 Serotonin transporter-independent actions of the antidepressant vortioxetine as revealed in studies of the Sert Met172 mouse
, European Neuropsychopharmacology 25: S264-S265 (2015)

P.1.g.054 Zinc reduces morphine dependence with no effect on pain perception in rats possible beneficial role of zinc supplementation in opioid-users
, European Neuropsychopharmacology 25: S265-S266 (2015)

P.1.g.055 Intranasal oxytocin dampens amygdala reactivity and normalises amygdala connectivity in Ptsd patients
, European Neuropsychopharmacology 25: S266-S267 (2015)

P1.g.057 Psychiatric adverse effects of adjunctive levetiracetam for epilepsy in children and adolescents
, European Neuropsychopharmacology 25: S267-S268 (2015)

P.1.g.059 Further evidences of the efficacy of agomelatine in animal models of neuropathic pain
, European Neuropsychopharmacology 25: S268-S269 (2015)

P.1.g.062 Combined administration of oral tranylcypromine and intravenous S-ketamine in treatment-resistant depression: A case report
, European Neuropsychopharmacology 25: S270-S271 (2015)

P.1.g.065 Excitatory glutamate component involved in the electrophysiological response of ventral tegmental area dopamine neurons to methylphenidate
, European Neuropsychopharmacology 25: S271-S272 (2015)

P.1.g.066 Proteolytic hydrolysis of myelin basic protein by IgGs during long-term treatment of schizophrenia
, European Neuropsychopharmacology 25: S272-S273 (2015)

P1.g.068 Phosphorylation of Trpv1 located within the dorsal periaqueductal gray enhances social defeat stress-induced analgesia in mice
, European Neuropsychopharmacology 25: S273-S274 (2015)

P.1.g.070 Amygdala inactivation produces antinociception without changing threatening-induced pain inhibition in mice
, European Neuropsychopharmacology 25: S274-S275 (2015)

P1.g.074 Brexpiprazole alters monoaminergic systems following its subacute and long-term administration: an in vivo electrophysiological study
, European Neuropsychopharmacology 25: S276-S277 (2015)

P.1.g.077 The discovery of Rg1578: a metabotropic glutamate receptor 2/3 negative allosteric modulator with antidepressant and cognitive enhancing properties
, European Neuropsychopharmacology 25: S278-S279 (2015)

P.1.g.082 Activation of cannabinoid system in nucleus accumbens affects cost-benefit decision making
, European Neuropsychopharmacology 25: S279-S280 (2015)

P.1.g.084 Could luminosity be part of the placebo effect in antidepressant trials?
, European Neuropsychopharmacology 25: S280-S281 (2015)

P.1.h.003 Effect of congenital and acquired hypothyroidism on forced swimming test in juvenile rats
, European Neuropsychopharmacology 25: S282-S283 (2015)

P.1.h.005 The deficit in anticipatory motivation as a negative symptom of schizophrenia: phencyclidine treated rats exhibit pessimism in an optimistic bias task
, European Neuropsychopharmacology 25: S283-S284 (2015)

P.1.h.006 Effects of antipsychotic drugs asenapine, paliperidone, quetiapine and aripiprazole on pain and locomotion in mice
, European Neuropsychopharmacology 25: S284-S285 (2015)

P.1.h.008 Social behaviour in deer mice as a novel interactive paradigm of relevance for obsessive-compulsive disorder (Ocd)
, European Neuropsychopharmacology 25: S285-S286 (2015)

P1.h.010 Behavioural characterisation of dehydroepiandrosterone effects in rats: further evaluation and the role of Gaba(A) receptors
, European Neuropsychopharmacology 25: S286-S287 (2015)

P.1.h.011 Effects of positive 5-selective modulation of Gabaa receptors on amphetamine-induced hyperactivation
, European Neuropsychopharmacology 25: S287-S288 (2015)

P.1.h.014 Time dependent sensitisation exaggerates depressive-like symptoms in Flinders sensitive line (Fsl) rats, a genetic animal model of depression
, European Neuropsychopharmacology 25: S288-S289 (2015)

P.1.h.016 Impact of stress on neuronal plasticity in rats
, European Neuropsychopharmacology 25: S289-S290 (2015)

P.1.h.018 Enhancement of locomotor activity following intraseptal Nmda glutamate receptor agonist injection in high and low responders to novelty
, European Neuropsychopharmacology 25: S290-S291 (2015)

P.1.h.021 Effect of fluoxetine and Miml411, a novel tropomyosin-related kinase receptor agonist, in a lipopolysaccharide-induced model of depression
, European Neuropsychopharmacology 25: S292-S293 (2015)

P.1.h.024 Chronic magnesium administration ameliorates depressive- and anxiety-like behaviour in Acth-treated rats
, European Neuropsychopharmacology 25: S294-S295 (2015)

P.1.h.026 The effects of repeated disulfiram and nitroglycerin on thermonociception and visceral pain in mice
, European Neuropsychopharmacology 25: S295-S296 (2015)

P.1.h.030 Enduring erasure of remote fear memories by the blockade of calcium-permeable Ampa receptors applied before extinction training
, European Neuropsychopharmacology 25: S297-S298 (2015)

P.1.h.031 Functional reorganization of the mesolimbic dopaminergic system after its terminal area glutamate injection
, European Neuropsychopharmacology 25: S298-S299 (2015)

P.1.i.001 Neurocognitive effects of repetitive transcranial magnetic stimulation in drug free treatment-resistant depression patients
, European Neuropsychopharmacology 25: S299-S300 (2015)

P.1.i.004 Lead-induced impairments in neural processes in relation to executive function
, European Neuropsychopharmacology 25: S300-S301 (2015)

P.1.i.007 Glutamatergic activity measured by 1H-Mrs is decreased in euthymic bipolar I disorder subjects
, European Neuropsychopharmacology 25: S302-S303 (2015)

P.1.i.010 Spectroscopy differences between at risk populations for psychosis
, European Neuropsychopharmacology 25: S304-S305 (2015)

P.1.i.012 Serotonin transporter genotype moderates the effect of psychosocial stress on executive control and default mode network connectivity
, European Neuropsychopharmacology 25: S305-S306 (2015)

P.1.i.013 Neural correlates of reactive aggression in psychopathic violent offenders; a functional magnetic resonance study
, European Neuropsychopharmacology 25: S306-S307 (2015)

P.1.i.015 Impulsive aggression in misophonia: results from a functional magnetic resonance imaging study
, European Neuropsychopharmacology 25: S307-S308 (2015)

P.1.i.016 Fronto-insular network and prefrontal Gaba levels following targeted transcranial theta-burst magnetic stimulation
, European Neuropsychopharmacology 25: S308-S309 (2015)

P.1.i.018 Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: test-retest reproducibility and comparison with [18F]altanserin
, European Neuropsychopharmacology 25: S309-S310 (2015)

P.1.i.020 Changes in apparent diffusion coefficient values in patients with multiple sclerosis with regard to treatment with interferon beta
, European Neuropsychopharmacology 25: S310-S311 (2015)

P.1.i.021 Improvement of well-being measures after regular physical exercise correlates with resting state connectivity in attentional and default mode networks
, European Neuropsychopharmacology 25: S311-S312 (2015)

P.1.i.023 Self-regulation of the dopaminergic reward system via real time fMri neurofeedback: a novel treatment approach for cocaine addiction
, European Neuropsychopharmacology 25: S312-S313 (2015)

P.1.i.025 Brain Pet measurement of phosphodiesterase 10A occupancy by Tak-063, a new phosphodiesterase 10A inhibitor, using [11C]T-773 in nonhuman primates
, European Neuropsychopharmacology 25: S313-S314 (2015)

P.1.i.026 Vortioxetine reduces Bold signal during performance of the N-back task in subjects remitted from depression and healthy control participants
, European Neuropsychopharmacology 25: S314-S315 (2015)

P1.i.029 Effect of catechol-O-methyltransferase polymorphism on subcortical volumes in schizophrenia
, European Neuropsychopharmacology 25: S316-S317 (2015)

P.1.i.030 The modulatory role of catechol-O-methyltransferase Val158Met polymorphism on the association between white matter microstructure and cognitive performances in schizophrenia
, European Neuropsychopharmacology 25: S317-S318 (2015)

P.1.i.032 Interpolation of sparse mRna samples to create comprehensive atlases of cerebral protein transcription
, European Neuropsychopharmacology 25: S318-S319 (2015)

P.1.i.034 Gene expression and protein distribution of serotonergic key proteins in the human brain revealed by Pet in vivo and postmortem quantification
, European Neuropsychopharmacology 25: S319-S320 (2015)

P.1.i.035 Differentiation between first-episode psychosis patients and healthy subjects on the basis of precuneus activation
, European Neuropsychopharmacology 25: S320-S321 (2015)

P.1.i.037 Effects of norepinephrine transporter gene variants on protein binding in patients with Adhd using Pet
, European Neuropsychopharmacology 25: S321-S322 (2015)

P.1.i.038 Activity in the parahippocampal gyrus during cognitive tasks correlates with the tendency to ruminate
, European Neuropsychopharmacology 25: S322-S323 (2015)

P.1.i.040 Effects of intranasal oxytocin on reward anticipation in patients with post-traumatic stress disorder: an fMri study
, European Neuropsychopharmacology 25: S323-S324 (2015)

P.1.i.041 A retrospective open-label study to compare antidepressant efficacy of repetitive transcranial magnetic stimulation using two different devices
, European Neuropsychopharmacology 25: S324-S325 (2015)

P.1.i.043 Age-dependent effects of selective serotonin reuptake inhibitor exposure on the development of the Gaba-ergic system
, European Neuropsychopharmacology 25: S325-S326 (2015)

P.1.i.044 The effects of methylphenidate on striatal dopamine system are dependent on age: a pharmacological magnetic resonance imaging study
, European Neuropsychopharmacology 25: S326-S327 (2015)

P.1.i.047 Interregional changes in serotonin transporter availability upon treatment with selective serotonin reuptake inhibitors
, European Neuropsychopharmacology 25: S327-S328 (2015)

P.1.i.051 Intermittent Theta Burst Stimulation of the left dorsolateral prefrontal cortex for the treatment of persistent negative symptoms in schizophrenia
, European Neuropsychopharmacology 25: S329-S330 (2015)

P.1.i.053 Low behavioural pattern separation is linked to reduced dentate gyrus activation during fear generalisation
, European Neuropsychopharmacology 25: S330-S331 (2015)

P.1.i.055 Generalized anxiety disorder is characterised by a non-discriminative response of the ventromedial prefrontal cortex during fear learning
, European Neuropsychopharmacology 25: S331-S332 (2015)

P.1.j.001 Cognitive deficit and social functioning in patients with first psychotic episode
, European Neuropsychopharmacology 25: S332-S333 (2015)

P.1.j.003 Neuropsychological profiles in periventricular nodular heterotopia
, European Neuropsychopharmacology 25: S333-S334 (2015)

P.1.j.004 Effects of etifoxine on passive avoidance tests and locomotor activity in rats
, European Neuropsychopharmacology 25: S334-S335 (2015)

P.1.j.006 New neurocognitive endophenotype for major depressive episode: the role of working memory and implicit learning in the acute phase of depression
, European Neuropsychopharmacology 25: S335-S336 (2015)

P.1.j.009 Awareness of driving impairment: lapses versus excursions out-of-lane during highway driving
, European Neuropsychopharmacology 25: S337-S338 (2015)

P.1.j.012 Memantine treatment does not improve spatial learning in medial septal lesioned rats
, European Neuropsychopharmacology 25: S339-S340 (2015)

P.1.j.014 Effects of gallic acid and quercetin on learning and memory processes in young/healthy rats
, European Neuropsychopharmacology 25: S340-S341 (2015)

P.1.j.017 Effects of chronic etanercept, a Tnf- inhibitor, on cognitive dysfunction in cafeteria diet-fed rats
, European Neuropsychopharmacology 25: S342-S343 (2015)

P.1.j.020 Functioning of the posterior cingulate cortex predicts development of insight into one's illness in patients with first-episode psychosis
, European Neuropsychopharmacology 25: S343-S344 (2015)

P.1.j.022 Cognitive remediation in psychiatric patients with an online cognitive game and assessment tool
, European Neuropsychopharmacology 25: S344-S345 (2015)

P.1.j.023 Alleviation of stress-induced cognitive decline by telmisartan goes beyond peroxisome proliferator-activated receptor gamma agonism, targeting Hpa axis deactivation
, European Neuropsychopharmacology 25: S345-S346 (2015)

P.1.j.025 Effects of acute stress and anxiety induced by the inhalation of air enriched with Co2 on model-based and model-free behaviour
, European Neuropsychopharmacology 25: S346-S347 (2015)

P.1.j.026 The retinal pathways as a model to understand brain damages in cannabis users
, European Neuropsychopharmacology 25: S347-S348 (2015)

P.1.j.028 Differences in affective go/no go performance during acute stress and anxiety induced by Co2-enriched air are moderated by reaction time
, European Neuropsychopharmacology 25: S348-S349 (2015)

P.1.j.030 Are schizophrenia patients worse performers of dual-tasking? Insights from motor timing
, European Neuropsychopharmacology 25: S349-S350 (2015)

P.1.j.032 Protective effects of metformin in scopolamine-induced cognitive impairment in rats
, European Neuropsychopharmacology 25: S350-S351 (2015)

P.1.j.034 Error processing and psychopathy in multiproblem young adults: preliminary Eeg results
, European Neuropsychopharmacology 25: S351-S352 (2015)

P.1.j.037 Imaging neurophysiological dynamics underlying cognitive performance in a rat touch-screen reversal learning paradigm
, European Neuropsychopharmacology 25: S353-S354 (2015)

P.1.k.001 Clinical conditions relevant to the depressive mental states of Japanese patients with subacute myelo-optic neuropathy (Smon)
, European Neuropsychopharmacology 25: S354-S355 (2015)

P.1.k.003 Borderline personality disorder experience in mental health centre
, European Neuropsychopharmacology 25: S355-S356 (2015)

P.1.k.006 Collaborative care between clinical pharmacists and general practitioners in patients with polypharmacy: a focus on psychiatric and neurological drugs
, European Neuropsychopharmacology 25: S356-S357 (2015)

P.1.k.008 Prevalence and factors related to depressive symptoms among Korean university students
, European Neuropsychopharmacology 25: S357-S358 (2015)

P.1.k.009 Borderline personality disorder revealed in Armenian population using Dsm-5 criteria as screening tool
, European Neuropsychopharmacology 25: S358-S359 (2015)

P.1.k.011 Examination of self-esteem, body image, and past incidents of trauma in patients with obesity
, European Neuropsychopharmacology 25: S359-S360 (2015)

P.1.k.013 Predictors of subjective successful aging in community-dwelling elderly: Comparing elders living alone and those living with others
, European Neuropsychopharmacology 25: S360-S361 (2015)

P.1.k.015 Sleep quality in psychiatric outpatients
, European Neuropsychopharmacology 25: S361-S362 (2015)

P.1.k.016 Turkish reliability and validity of psychopathy checklist revised
, European Neuropsychopharmacology 25: S362-S363 (2015)

P.1.k.018 Associations among psychosocial factor, medical factor and quality of life in patients with end-stage renal disease
, European Neuropsychopharmacology 25: S363-S364 (2015)

P.1.k.020 Prevalence of depressive symptoms and cognitive deterioration in elderly people
, European Neuropsychopharmacology 25: S364-S365 (2015)

P.1.k.022 Changes of illicit opioid use among Hiv-infected opioid users in Russia (20042014)
, European Neuropsychopharmacology 25: S365-S366 (2015)

P.1.k.023 The prevalence and impact on insomnia of periodic limb movements during sleep in the Korean elderly
, European Neuropsychopharmacology 25: S366-S367 (2015)

P.1.k.026 The sociodemographic characteristics, habits, trends and forensic aspects of young male soldiers who applied to psychiatry clinic
, European Neuropsychopharmacology 25: S367-S368 (2015)

P.1.k.028 The prevalence of adult separation anxiety disorder in patients with attention-deficit/hyperactivity disorder: a preliminary study from Turkey
, European Neuropsychopharmacology 25: S368-S369 (2015)

P1.k.030 Neuropsychological functioning as a risk factor for depression and anxiety disorders: A 10-year study in young people with parental psychopathology
, European Neuropsychopharmacology 25: S369-S370 (2015)

P.1.k.031 Personality traits and emotional profiles in severely obese patients in a preoperative evaluation
, European Neuropsychopharmacology 25: S370-S371 (2015)

P.1.k.033 A new platform to improve quality of Panns and Madrs administration
, European Neuropsychopharmacology 25: S371-S372 (2015)

P1.k.035 Gender difference among involuntarily admitted patients in a psychiatric service during 2014
, European Neuropsychopharmacology 25: S372-S373 (2015)

P.1.k.037 Prescription survey of orexin receptor antagonist suvorexant
, European Neuropsychopharmacology 25: S373-S374 (2015)

P.2.a.001 Effect of sesamol pretreatment against lipopolysaccharide-induced depressive and anxiety-like behaviour in Swiss albino mice
, European Neuropsychopharmacology 25: S374-S375 (2015)

P.2.a.002 Experimental investigation on the effects of some antidepressants on spatial memory performance of old rats
, European Neuropsychopharmacology 25: S375-S376 (2015)

P.2.a.004 Sustained aromatase inhibition: brain effects in both sexes
, European Neuropsychopharmacology 25: S376-S377 (2015)

P.2.a.007 The potential antidepressant effect of the joint administration of ketamine and mGlu2/3 receptor antagonist, Ly341495 in the forced swim test in rats
, European Neuropsychopharmacology 25: S378-S379 (2015)

P.2.a.009 Chronic administration of buprenorphine in combination with samidorphan produces antidepressant-like effects in rats without locomotor sensitization
, European Neuropsychopharmacology 25: S379-S380 (2015)

P.2.a.010 Analysis of the rat hippocampal microRna expression profile following chronic electroconvulsive stimulation
, European Neuropsychopharmacology 25: S380-S381 (2015)

P.2.a.012 Co-administration of fluoxetine with acetylsalicylic acid, but not flurbiprofen or celecoxib, for one week shows an antidepressant-like effect
, European Neuropsychopharmacology 25: S381-S382 (2015)

P.2.a.014 Effect of subacute and long-term administration of vortioxetine on firing activity of catecholaminergic neurons
, European Neuropsychopharmacology 25: S382-S383 (2015)

P.2.b.002 Life events in childhood and before onset in major depression. prevalence, specificity and their impact on disease features and causal relationships
, European Neuropsychopharmacology 25: S385-S386 (2015)

P.2.b.004 Homocysteine and asymmetric dimethylarginine in bipolar depression: the effect of pharmacological treatment
, European Neuropsychopharmacology 25: S386-S387 (2015)

P.2.b.007 Depression and the cognitive distortions among the patients with end stage renal disease
, European Neuropsychopharmacology 25: S388-S389 (2015)

P.2.b.009 Environmental effects on suicidal behaviour: association of drinking-water arsenic levels and suicide
, European Neuropsychopharmacology 25: S389-S390 (2015)

P.2.b.015 Which pregnant bipolar women have an increased risk of delayed psychiatric treatment?
, European Neuropsychopharmacology 25: S392-S393 (2015)

P.2.b.016 A longitudinal study of the relationships between anhedonia and functioning in a large cohort of depressed patients treated by general practitioners
, European Neuropsychopharmacology 25: S393-S394 (2015)

P.2.b.017 Structural brain alterations in major depression: findings from the Enigma Major Depressive Disorder Working Group
, European Neuropsychopharmacology 25: S394-S395 (2015)

P.2.b.019 Association between clinical response to duloxetine treatment and brain-derived neurotrophic factor or catecholamine metabolites
, European Neuropsychopharmacology 25: S395-S396 (2015)

P.2.b.021 Pharmacologic treatment patterns and social functioning in depressive outpatients
, European Neuropsychopharmacology 25: S396-S397 (2015)

P.2.b.022 Antidepressant effect and tolerabilty of agomelatine in smokers/non-smokers/ex-smokers: results of a subgroup-analysis over 6 months (Vital-study)
, European Neuropsychopharmacology 25: S397-S398 (2015)

P.2.b.024 Psychosocial burden of unipolar and bipolar depression in the course of disease during three subsequent depressive episodes
, European Neuropsychopharmacology 25: S398-S399 (2015)

P.2.b.027 Impaired down-regulation of negative emotion in self-referent social situations in bipolar disorder: a pilot study of a novel experimental paradigm
, European Neuropsychopharmacology 25: S400-S401 (2015)

P.2.b.030 The validation of Premenstrual Symptoms Screening Tool (Psst) in the Greek population: Preliminary results
, European Neuropsychopharmacology 25: S401-S402 (2015)

P.2.b.031 Stressful life events, memory performance and Hpa axis negative feedback sensitivity in major depression: a structural equation modelling approach
, European Neuropsychopharmacology 25: S402-S403 (2015)

P.2.b.033 Siltuximab improves depressive symptoms in a randomised, placebo-controlled, phase 2 study in patients with multicentric Castlemen's disease
, European Neuropsychopharmacology 25: S403-S404 (2015)

P.2.b.035 Agomelatine safety: monitoring liver function in observational study
, European Neuropsychopharmacology 25: S404-S405 (2015)

P.2.b.036 The outcome of major depressive disorder comorbid diabetes
, European Neuropsychopharmacology 25: S405-S406 (2015)

P.2.C.002 Gene expression profile of Dgkh risk variant carriers with bipolar disorder
, European Neuropsychopharmacology 25: S406-S407 (2015)

P.2.c.004 Safety and tolerability of antipsychotic-mood stabilizer co-treatment in acute bipolar disorder; a systematic review and exploratory meta-analysis
, European Neuropsychopharmacology 25: S407-S408 (2015)

P.2.c.006 Extensity and dispersion of personality disorder in bipolar patients
, European Neuropsychopharmacology 25: S408-S409 (2015)

P.2.c.007 Neurotrophic mechanisms of candesartan in an animal model of mania induced by D-amphetamine
, European Neuropsychopharmacology 25: S409-S410 (2015)

P.2.d.001 Cortisol levels in nails and neurocognitive performance in euthymic bipolar I patients and healthy controls
, European Neuropsychopharmacology 25: S410-S411 (2015)

P.2.d.004 Influence of body mass index on quality of life in patients with bipolar disorder
, European Neuropsychopharmacology 25: S412-S413 (2015)

P.2.d.006 The validity of the modified Korean version of the mood disorder questionnaire
, European Neuropsychopharmacology 25: S413-S414 (2015)

P.2.d.009 Cyamemazine and pancytopenia in a bipolar patient with psychosomatic complaints
, European Neuropsychopharmacology 25: S415-S416 (2015)

P.2.d.011 Increased mean platelet volume in patients with bipolar disorder in manic and euthymic states
, European Neuropsychopharmacology 25: S416-S417 (2015)

P.2.d.014 Categorical improvement across mania symptoms: pooled analyses of cariprazine phase Ii/Iii trials
, European Neuropsychopharmacology 25: S418-S419 (2015)

P.2.d.015 Short telomeres in subjects with remitted bipolar disorder
, European Neuropsychopharmacology 25: S419-S420 (2015)

P.2.d.017 Lurasidone in the long-term treatment of patients with bipolar i disorder: responder and remitter status during a 24-week open-label extension study
, European Neuropsychopharmacology 25: S420-S421 (2015)

P.2.d.019 Functioning, theory of mind, and cognitive dysfunction in bipolar disorder
, European Neuropsychopharmacology 25: S421-S422 (2015)

P.2.d.020 Enlarged inferior frontal gyrus volume might be a structural endophenotype for bipolar disorder: A voxel-based morphometry study
, European Neuropsychopharmacology 25: S422-S423 (2015)

P.2.d.022 Mental disorders in offspring of parents with bipolar disorder
, European Neuropsychopharmacology 25: S423-S424 (2015)

P.2.d.023 Effects of the interaction between lithium and glycogen synthase kinase 3 in effective connectivity on neural response to emotional processing in bipolar disorder
, European Neuropsychopharmacology 25: S424-S425 (2015)

P.2.d.026 A model to uncover bipolarity in recurrent depressive episodes
, European Neuropsychopharmacology 25: S425-S426 (2015)

P.2.d.028 Emotion dysregulation and bipolar I disorder
, European Neuropsychopharmacology 25: S426-S427 (2015)

P.2.d.031 Integrated mania management: an observational study at the rehabilitative mood disorder unit of San Raffaele hospital in Milan
, European Neuropsychopharmacology 25: S427-S428 (2015)

P.2.d.033 Role of cortical thickness as an endophenotype for bipolar disorder: a vertex-wise analysis in bipolar disorder patients and first degree relatives
, European Neuropsychopharmacology 25: S428-S429 (2015)

P.2.d.035 Bioequivalence of blood and salivary levels of lithium and valproate: Implications for the clinical management of bipolar disorder
, European Neuropsychopharmacology 25: S429-S430 (2015)

P.2.d.037 Telemedicine in bipolar disorder
, European Neuropsychopharmacology 25: S430-S431 (2015)

P.2.e.003 Effect of acute administration of agomelatine on the memory processes triggered by threat responses to an auditory stimulus in rats
, European Neuropsychopharmacology 25: S432-S433 (2015)

P.2.e.007 Antipsychotic drugs in depression: the unexplored role of neuroplasticity
, European Neuropsychopharmacology 25: S433-S434 (2015)

P.2.f.002 The effect of ketamine anesthesia on the efficacy of electroconvulsive therapy and cognitive functions in treatment-resistant depression
, European Neuropsychopharmacology 25: S434-S435 (2015)

P.2.f.004 Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression
, European Neuropsychopharmacology 25: S435-S436 (2015)

P.2.f.007 Comparison of aripiprazole versus bupropion augmentation for treatment of older patients with Mdd: a randomized prospective open-label multi-center study
, European Neuropsychopharmacology 25: S437-S438 (2015)

P.2.f.010 Treatment adherence and response to psychopharmacological treatment in borderline personality disorder with and without major depressive disorder
, European Neuropsychopharmacology 25: S439-S440 (2015)

P.2.f.012 Depression in multiple sclerosis focusing on treatment possibilities
, European Neuropsychopharmacology 25: S440-S441 (2015)

P.2.f.015 Omega-3 polyunsaturated fatty acids for major depressive disorder: an updated meta-analysis of randomised clinical trials
, European Neuropsychopharmacology 25: S442-S443 (2015)

P.2.f.016 Long-term outcomes in treatment of depression with venlafaxine Er 75225 mg/d in the acute and continuation phases (Prevent study)
, European Neuropsychopharmacology 25: S443-S444 (2015)

P2.f.018 Effect of adjunctive brexpiprazole (Opc-34712) on depressive symptoms in patients with symptoms of anxious distress: results from post-hoc analyses
, European Neuropsychopharmacology 25: S444-S445 (2015)

P.2.f.019 Liver function test abnormalities in depressed patients treated with antidepressants: an observational cohort study in a psychiatric department
, European Neuropsychopharmacology 25: S445-S446 (2015)

P.2.f.025 Switching from inadequate adjunctive treatments: Open-label study of brexpiprazole effects on depressive symptoms, cognitive and physical functioning
, European Neuropsychopharmacology 25: S448-S449 (2015)

P.2.f.028 Antidepressant efficacy of S-adenosyl-L-methionine in major depressive disorder
, European Neuropsychopharmacology 25: S450-S451 (2015)

P.2.g.002 Vortioxetine blocks serotonin excitation of Gabaergic interneurons and disinhibits pyramidal cell activity in the rat hippocampus
, European Neuropsychopharmacology 25: S451-S452 (2015)

P.2.g.003 Suicidal ideation in primary care patients: comorbidity with depression, anxiety disorders, and somatic diagnoses
, European Neuropsychopharmacology 25: S452-S453 (2015)

P.2.h.001 Plasma apolipoprotein E and severity of suicidal behaviour
, European Neuropsychopharmacology 25: S453-S454 (2015)

P.2.h.004 The changes of psychometric profiles after treatment of lower urinary tract symptoms suggestive of benign prostate hyperplasia
, European Neuropsychopharmacology 25: S455-S456 (2015)

P.2.h.006 Papa: Pharmacokinetics in Pregnancy and Antidepressant drugs
, European Neuropsychopharmacology 25: S456-S457 (2015)

P.2.h.009 Maintenance of vortioxetine efficacy with long-term treatment of patients with major depressive disorder
, European Neuropsychopharmacology 25: S458-S459 (2015)

P.2.h.011 Meta-analysis of cognitive function in vortioxetine clinical trials in major depressive disorder
, European Neuropsychopharmacology 25: S459-S460 (2015)

P.2.h.014 Treatment with fluoxetine in adolescents may aggravate emotional dysregulation: a power analysis for future studies
, European Neuropsychopharmacology 25: S461-S462 (2015)

P.3.b.001 Exploring shared and variant alterations in brain function between schizophrenia and bipolar disorder using resting-state fMri
, European Neuropsychopharmacology 25: S462-S463 (2015)

P.3.b.002 Cortex morphology and subcortical brain grey matter deficits in schizophrenia and unaffected relatives
, European Neuropsychopharmacology 25: S463-S464 (2015)

P3.b.004 Comt Drd2 epistasis modulates a putative emotional connectomic intermediate phenotype for schizophrenia
, European Neuropsychopharmacology 25: S464-S465 (2015)

P.3.b.005 Theory of mind, experiential negative symptoms and schizophrenia
, European Neuropsychopharmacology 25: S465-S466 (2015)

P.3.b.007 Insight in schizophrenia: the role of neurocognitive functioning in relation to psychopathology
, European Neuropsychopharmacology 25: S466-S467 (2015)

P.3.b.010 Low erythrocyte catalase activity in patients with schizophrenia
, European Neuropsychopharmacology 25: S468-S469 (2015)

P.3.b.012 Duration of untreated psychosis and cognitive impairment
, European Neuropsychopharmacology 25: S469-S470 (2015)

P.3.b.013 Adolescents with family history of psychosis and the effect of family environment on the antioxidant defense system
, European Neuropsychopharmacology 25: S470-S471 (2015)

P.3.b.015 Positive encenicline exposure-response relationships for cognition and clinical function in schizophrenia patients receiving atypical antipsychotics
, European Neuropsychopharmacology 25: S471-S472 (2015)

P.3.b.018 Gene polymorphisms of oxidative stress and glutamatergic system in schizophrenic patients with tardive dyskinesia
, European Neuropsychopharmacology 25: S473-S474 (2015)

P.3.b.020 The association between dorsolateral prefrontal N-acetylaspartate and insight in psychotic disorders
, European Neuropsychopharmacology 25: S474-S475 (2015)

P.3.b.021 Interleukin-1, cognition and metabolic syndrome in schizophrenia
, European Neuropsychopharmacology 25: S475-S476 (2015)

P.3.b.023 Decreased intrinsic connectivity within mesocortical networks associated with apathy in patients with schizophrenia
, European Neuropsychopharmacology 25: S476-S477 (2015)

P.3.b.024 Changes in white matter microstructure integrity of the limbic system after psychosis in 22q11 deletion syndrome seems to be associated with psychosis
, European Neuropsychopharmacology 25: S477-S478 (2015)

P.3.c.002 Selective prolyl oligopeptidase inhibition by Ipr19 as a new pharmacological treatment of the cognitive impairment associated with schizophrenia
, European Neuropsychopharmacology 25: S479-S480 (2015)

P.3.c.005 Impact of antipsychotic treatment on levels of glucose, cholesterol and triacylglycerol in serum of rats perinatally treated with phencyclidine
, European Neuropsychopharmacology 25: S480-S481 (2015)

P.3.c.006 Study of the protein expression levels in the pre-frontal cortex of mice subjected to haloperidol chronic exposure
, European Neuropsychopharmacology 25: S481-S482 (2015)

P.3.d.002 The role of electroconvulsive therapy in the treatment of schizophrenia
, European Neuropsychopharmacology 25: S482-S483 (2015)

P.3.d.005 The preference survey for long-acting injectable antipsychotics of community-dwelling patients with schizophrenia and their caregivers
, European Neuropsychopharmacology 25: S483-S484 (2015)

P.3.d.010 Effectiveness, tolerability and treatment adherence of high doses of paliperidone palmitate in patients with severe schizophrenia
, European Neuropsychopharmacology 25: S485-S486 (2015)

P.3.d.012 A randomized, 13-week study assessing the efficacy and safety of paliperidone palmitate and olanzapine in first-episode schizophrenic patients
, European Neuropsychopharmacology 25: S486-S487 (2015)

P.3.d.013 Weight gain and antipsychotics, data from Eufest study
, European Neuropsychopharmacology 25: S487-S488 (2015)

P.3.d.015 Supported employment program in first episode psychosis: clinical outcome improvements at 1 year follow up
, European Neuropsychopharmacology 25: S488-S489 (2015)

P.3.d.018 Efficacy and safety of aripiprazole and haloperidol in patients with schizophrenia
, European Neuropsychopharmacology 25: S490-S491 (2015)

P.3.d.021 Psychopharmacologic treatment in bipolar, schizoaffective and schizophrenic patients: a descriptive study
, European Neuropsychopharmacology 25: S492-S493 (2015)

P.3.d.025 Relationship between treatment compliance, insight and hospitalisations among schizophrenia patients
, European Neuropsychopharmacology 25: S493-S494 (2015)

P.3.d.029 Sodium nitroprusside in treatment-refractory schizophrenia: a case-report
, European Neuropsychopharmacology 25: S495-S496 (2015)

P.3.d.032 Study of efficiency and tolerance after changing from olanzapine and risperidone to oral paliperidone in a sample of patients with schizophrenia
, European Neuropsychopharmacology 25: S496-S497 (2015)

P.3.d.033 Study of efficiency, physical health and tolerance of paliperidone palmitate in patients with severe mental disorder
, European Neuropsychopharmacology 25: S497-S498 (2015)

P.3.d.035 Aripiprazole in treatment of first episode schizophrenia
, European Neuropsychopharmacology 25: S498-S499 (2015)

P.3.d.038 The effects of risperidone long-acting injection versus paliperidone palmitate on cognitive and social function in schizophrenia an open pilot randomised controlled trial
, European Neuropsychopharmacology 25: S500-S501 (2015)

P.3.d.040 Paliperidone palmitate versus conventional depots and oral antipsychotics in inpatients with schizophrenia
, European Neuropsychopharmacology 25: S501-S502 (2015)

P.3.d.041 Efficacy and safety of extended-release paliperidone in patients at high risk of drug-drug interaction
, European Neuropsychopharmacology 25: S502-S503 (2015)

P.3.d.042 Treatment discontinuation in schizophrenia. Paliperidone palmitate versus oral antipsychotics
, European Neuropsychopharmacology 25: S503-S504 (2015)

P.3.d.044 Self-reported antipsychotic adherence among outpatients with a severe mental disorder: a comparative study
, European Neuropsychopharmacology 25: S504-S505 (2015)

P.3.d.047 Metabolic syndrome and functionality 2-year follow-up study of 33 outpatients with a mental disorder treatment with paliperidone palmitate
, European Neuropsychopharmacology 25: S506-S507 (2015)

P.3.d.049 Effects of antipsychotic switch on body weight, blood data, and vital signs in patients with acute-phase schizophrenia: a retrospective study
, European Neuropsychopharmacology 25: S507-S508 (2015)

P.3.d.051 A descriptive study of the administration of paliperidone palmitate in a rural area
, European Neuropsychopharmacology 25: S508-S509 (2015)

P.3.d.052 Paliperidone palmitate effects on the electrocardiogram in Japanese patients with schizophrenia
, European Neuropsychopharmacology 25: S509-S510 (2015)

P.3.d.054 Blonanserin versus aripiprazole for treatment of Japanese schizophrenia patients: a randomized control trial
, European Neuropsychopharmacology 25: S510-S511 (2015)

P.3.d.056 Deltoid injection of aripiprazole once-monthly in the treatment of schizophrenia
, European Neuropsychopharmacology 25: S511-S512 (2015)

P.3.d.057 Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial
, European Neuropsychopharmacology 25: S512-S513 (2015)

P.3.d.059 Plasma levels of second generation antipsychotics as indicators of clinical response and severity of side-effects in first-episode psychosis patients
, European Neuropsychopharmacology 25: S513-S514 (2015)

P.3.d.060 Comparative clinical outcomes of orodispersable versus standard oral olanzapine tablets in non-adherent patients with schizophrenia or bipolar disorder
, European Neuropsychopharmacology 25: S514-S515 (2015)

P.3.d.062 Paliperidone palmitate: evaluation of effectiveness using a mirror image study
, European Neuropsychopharmacology 25: S515-S516 (2015)

P.3.d.066 Qtc prolongation and antipsychotics: a connection to remember
, European Neuropsychopharmacology 25: S518-S519 (2015)

P.3.d.069 How many patients with schizophrenia do not respond to antipsychotic drugs?
, European Neuropsychopharmacology 25: S520-S521 (2015)

P.3.d.071 The effect of brexpiprazole (Opc-34712) in adult outpatients with early-episode schizophrenia: An exploratory study
, European Neuropsychopharmacology 25: S521-S522 (2015)

P.3.d.072 Efficacy and safety of brexpiprazole (Opc-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
, European Neuropsychopharmacology 25: S522-S523 (2015)

P.3.d.074 Antipsychotic polytherapy and risk of readmission in a mental health hospitalisation unit. A cohort retrospective study
, European Neuropsychopharmacology 25: S523-S524 (2015)

P.3.d.075 Once-monthly paliperidone palmitate compared with oral conventional or oral atypical antipsychotic treatment in patients with schizophrenia
, European Neuropsychopharmacology 25: S524-S525 (2015)

P.3.d.077 Clinical Global Impression after aripiprazole once-monthly and paliperidone palmitate: Results from Qualify, a head-to-head study in schizophrenia
, European Neuropsychopharmacology 25: S525-S526 (2015)

P.3.d.080 Aripiprazole once-monthly and paliperidone palmitate in patients with schizophrenia stratified by age: Results from Qualify, a head-to-head study
, European Neuropsychopharmacology 25: S527-S528 (2015)

P.3.d.082 Enhancing cognitive remediation therapy with transcranial direct current stimulation: preliminary findings in schizophrenia
, European Neuropsychopharmacology 25: S528-S529 (2015)

P.3.d.084 Aripiprazole once-monthly is superior to paliperidone palmitate: results from Qualify, a randomized, head-to-head clinical study in schizophrenia
, European Neuropsychopharmacology 25: S529-S530 (2015)

P.3.d.087 Tobacco smoking in patients taking antipsychotic long-acting injections and sexual dysfunction
, European Neuropsychopharmacology 25: S531-S532 (2015)

P.3.d.089 Changes in body mass and metabolic profiles over 12 months in patients with first-episode schizophrenia treated with flupenthixol decanoate
, European Neuropsychopharmacology 25: S532-S533 (2015)

P.3.d.092 Impact on hospitalisation of long acting injectable paliperidone in a first episode sample (Lehenak program)
, European Neuropsychopharmacology 25: S534-S535 (2015)

P.3.d.094 Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
, European Neuropsychopharmacology 25: S535-S536 (2015)

P.3.f.001 Factors associated with re-hospitalizations in schizophrenia: a community mental health service research
, European Neuropsychopharmacology 25: S536-S537 (2015)

P.3.f.003 In search of an affordable post-discharge intervention for patients with severe mental illness in a developing country
, European Neuropsychopharmacology 25: S537-S538 (2015)

P.3.f.005 Depressive symptoms in patients with schizophrenia
, European Neuropsychopharmacology 25: S538-S539 (2015)

P.3.f.008 Specificity of mental disorders and social danger as prognostic factor of involuntary treatment of patients in mental hospital
, European Neuropsychopharmacology 25: S539-S540 (2015)

P.3.f.011 Effectiveness of audiovisual campaigns against the stigmatisation of schizophrenia
, European Neuropsychopharmacology 25: S541-S542 (2015)

P.3.f.013 Prevalence of medical comorbidity in patients with schizophrenia
, European Neuropsychopharmacology 25: S542-S543 (2015)

P.3.f.014 Effects of Panss audio/video recordings on the presence of identical scorings across visits
, European Neuropsychopharmacology 25: S543-S544 (2015)

P.3.f.016 Initial medical work-up in first episode psychosis
, European Neuropsychopharmacology 25: S544-S545 (2015)

P.3.f.018 Evolution of anhedonia and depressive symptoms in Romanian outpatients diagnosed with major depressive episode and treated with agomelatine
, European Neuropsychopharmacology 25: S545-S546 (2015)

P.3.f.019 The effect of thought disorders on remission of symptoms in schizophrenia
, European Neuropsychopharmacology 25: S546-S547 (2015)

P3.f.021 Baseline cardiometabolic risk in a cohort of first-episode schizophrenia patients
, European Neuropsychopharmacology 25: S547-S548 (2015)

P.3.f.024 Tract-based statistics in first episode psychosis: preliminary results depending on substance abuse comorbidity
, European Neuropsychopharmacology 25: S549-S550 (2015)

P.3.f.026 Season of birth in schizophrenia in a lower latitude country of northern hemisphere Bangladesh perspective
, European Neuropsychopharmacology 25: S550-S551 (2015)

P.4.a.001 Impulsivity features of patients with obsessive-compulsive disorder and relationship between impulsivity and obsession subtypes
, European Neuropsychopharmacology 25: S552-S553 (2015)

P4.a.003 Involvement of Cyp2C19 in stress-induced despair
, European Neuropsychopharmacology 25: S553-S554 (2015)

P.4.a.004 Fear extinction deficits and Bdnf dysregulation in mice with full 5-Ht2C receptor editing: a model for post-traumatic stress disorders?
, European Neuropsychopharmacology 25: S554-S555 (2015)

P.4.a.006 The role of nerve growth factor and its receptor in posttraumatic stress disorder
, European Neuropsychopharmacology 25: S555-S556 (2015)

P.4.b.001 Baseline heartbeat perception accuracy and short-term outcome of brief cognitive-behaviour therapy for panic disorder with agoraphobia
, European Neuropsychopharmacology 25: S556-S557 (2015)

P.4.b.002 Association of human micro Rnas miR-22 and miR-491 polymorphisms with panic disorder with or without agoraphobia in a Korean population
, European Neuropsychopharmacology 25: S557-S558 (2015)

P.4.b.004 Photosensitivity in panic disorder and effects of medication treatment
, European Neuropsychopharmacology 25: S558-S559 (2015)

P.4.b.007 The lucidity features and dream anxiety level in elderly patients with generalized anxiety disorder
, European Neuropsychopharmacology 25: S560-S561 (2015)

P.4.b.009 The white matter in obsessive compulsive disorder: effect of pharmacological treatment and symptom dimensions models
, European Neuropsychopharmacology 25: S561-S562 (2015)

P.4.b.010 Fear conditioning and Bdnf levels and genotype in obsessive-compulsive disorder patients pre and post treatment with sertraline: preliminary results
, European Neuropsychopharmacology 25: S562-S563 (2015)

P.4.c.004 Adult neuroplasticity as a pathological trigger of recurrence in depression
, European Neuropsychopharmacology 25: S564-S565 (2015)

P.4.c.007 Involvement of dorsal raphe subnuclei in the regulation of anxiety-related defensive behaviour after acute and chronic treatment with imipramine
, European Neuropsychopharmacology 25: S566-S567 (2015)

P.4.d.001 A schedule for tapering out clonazepam in panic disorder patients after long-term treatment
, European Neuropsychopharmacology 25: S567-S568 (2015)

P.4.d.004 The influence of baseline severity on antidepressant efficacy for anxiety disorders: a meta-analysis and meta-regression
, European Neuropsychopharmacology 25: S568-S569 (2015)

P.4.d.005 Combining clomipramine and paroxetine for treatment-resistant obsessive compulsive disorder
, European Neuropsychopharmacology 25: S569-S570 (2015)

P.4.d.007 Olanzapine augmentation in alleviating treatment-resistant nightmares and insomnia in patients with combat-related Ptsd
, European Neuropsychopharmacology 25: S570-S571 (2015)

P.4.d.008 Gender differences in benzodiazepines prescription in old age patients
, European Neuropsychopharmacology 25: S571-S572 (2015)

P.4.e.002 Traumatic brain injury induces post-traumatic stress disorder-like behaviors in mice: possible role of white matter alterations
, European Neuropsychopharmacology 25: S572-S573 (2015)

P.4.e.003 Social conditioning of neutral faces: A pilot-study on brain functioning in social anxiety patients and their unaffected first-degree relatives
, European Neuropsychopharmacology 25: S573-S574 (2015)

P.4.f.002 The cognitive profile of early-onset obsessive-compulsive disorder; does age matter?
, European Neuropsychopharmacology 25: S574-S575 (2015)

P.4.f.005 Bdnf transcripts modulation in the blood of subjects exposed to childhood trauma history
, European Neuropsychopharmacology 25: S576-S577 (2015)

P.5.a.002 Therapeutic effect of novel 7-methoxytacrine-donepezil like hybrids on cognitive deficit in rats a potentiality for Alzheimer's disease treatment
, European Neuropsychopharmacology 25: S577-S578 (2015)

P.5.a.005 Preventive effect of the natural monoterpene myrtenal on cognitive disorders in dement mice
, European Neuropsychopharmacology 25: S578-S579 (2015)

P.5.a.009 Effects of chronic streptozocin-induced diabetes on neural stem cell proliferation in the 5Xfad mouse model of Alzheimer's disease
, European Neuropsychopharmacology 25: S580-S581 (2015)

P.5.b.001 Cochrane review of valproate preparations for agitation in dementia
, European Neuropsychopharmacology 25: S581-S582 (2015)

P.5.b.003 The effect of memantine treatment for sleep disturbances in patients with alcohol-related dementia
, European Neuropsychopharmacology 25: S582-S583 (2015)

P.5.b.007 Mechanisms underpinning antipsychotic drug sensitivity in Alzheimer's disease
, European Neuropsychopharmacology 25: S584-S585 (2015)

P.5.b.009 Are antidepressant drugs safer than antipsychotics in the behavioural and psychological symptoms of dementia?
, European Neuropsychopharmacology 25: S585-S586 (2015)

P.5.c.002 Sphingosine kinase 1 mediated signalling in Parkinson's disease animal model. Neuroprotective effect of fingolimod and a D2/D3 dopamine receptor agonist
, European Neuropsychopharmacology 25: S586-S587 (2015)

P.5.d.003 Relationship between psychiatric and neurological diagnosis in patients presenting to an outpatient neurology service with cognitive complaints
, European Neuropsychopharmacology 25: S587-S588 (2015)

P.5.d.004 Psychiatric comorbidity in elderly patients with vascular cognitive disorder
, European Neuropsychopharmacology 25: S588-S589 (2015)

P.5.d.006 Neurosyphilis presenting with psychosis and dementia a case report
, European Neuropsychopharmacology 25: S589-S590 (2015)

P.5.d.007 Improved spatial memory under dopaminergic medication in Parkinson's disease patients with subclinical depressive symptoms
, European Neuropsychopharmacology 25: S590-S591 (2015)

P.5.f.001 The effectiveness of combination therapy with quetapine and valproic acid in delirium with aggressive tendency: a prospective, controlled trial study
, European Neuropsychopharmacology 25: S591-S592 (2015)

P.5.f.002 Effect of antidepressant and anxiolytics on development of diabetes mellitus inpatients with Alzheimer's disease
, European Neuropsychopharmacology 25: S592-S593 (2015)

P.5.f.005 Escitalopram in treatment of narcolepsy case report
, European Neuropsychopharmacology 25: S593-S594 (2015)

P.6.a.001 Alcohol exacerbates restraint stress-induced hippocampal damage and cognitive deficit: implication of poly(Adp)-ribose polymerase over-activation
, European Neuropsychopharmacology 25: S595-S596 (2015)

P.6.a.004 Habitual alcohol drinking behavior associated with active ghrelin and serotonin neurons in the amygdala and lateral hypothalamus
, European Neuropsychopharmacology 25: S597-S598 (2015)

P.6.a.007 Stopping hand and eye movements during acute alcohol intoxication
, European Neuropsychopharmacology 25: S598-S599 (2015)

P.6.b.002 Epidemiology and diffusion binge drinking phenomenon in an Italian population of young adults
, European Neuropsychopharmacology 25: S600-S601 (2015)

P.6.b.005 An fMri study of nalmefene on alcohol effects in reward anticipation in alcohol dependence
, European Neuropsychopharmacology 25: S602-S603 (2015)

P.6.b.007 Measurement of hangover severity: can a 1-item question replace multi-item scales?
, European Neuropsychopharmacology 25: S603-S604 (2015)

P.6.b.010 Comparison of Hpa axis response to the stimulation of psychological stress in abstinence period of alcoholism with first degree relatives and control
, European Neuropsychopharmacology 25: S604-S605 (2015)

P.6.b.011 Alexithymia in a sample of alcohol-dependent patients: clinical correlations and cognitive patterns
, European Neuropsychopharmacology 25: S605-S606 (2015)

P.6.b.013 Neurochemical and microstructural aberrancies in binge alcohol consumption
, European Neuropsychopharmacology 25: S606-S607 (2015)

P.6.b.014 Detection of alcohol problems: the sooner the best
, European Neuropsychopharmacology 25: S607-S608 (2015)

P.6.b.016 Disulfiram psychosis in the treatment of alcoholism
, European Neuropsychopharmacology 25: S608-S609 (2015)

P.6.c.001 Dopamine D2 receptor dynamic and modulation in the D2R-Sigma 1 heteroreceptor complexes: role in cocaine action
, European Neuropsychopharmacology 25: S609-S610 (2015)

P.6.c.004 Unveiling metabolic alterations within the human reward circuitry in addiction by using a novel small-voxel, 1H-Mrs (spectroscopy) protocol in the nucleus accumbens
, European Neuropsychopharmacology 25: S610-S611 (2015)

P.6.c.005 New generation of anxiolytics for treatment of opiate-like addiction: advantages and possible clinical application
, European Neuropsychopharmacology 25: S611-S612 (2015)

P.6.d.003 Baby bonzai: a case of maternal exposure to synthetic cannabinoid during pregnancy
, European Neuropsychopharmacology 25: S612-S613 (2015)

P.6.d.006 I was gonna process rewards but then I got high: the acute and chronic effects of cannabis and ketamine on reward processing
, European Neuropsychopharmacology 25: S614-S615 (2015)

P.6.d.009 Polyabuse and diversion of drugs: methylphenidate/cannabis-induced manic like-symptoms
, European Neuropsychopharmacology 25: S615-S616 (2015)

P.6.d.010 The 2D:4D digit ratio as biomarker for substance abuse
, European Neuropsychopharmacology 25: S616-S617 (2015)

P.6.d.012 Use of other substances among kratom users: findings from a 2011 national household survey in Thailand
, European Neuropsychopharmacology 25: S617-S618 (2015)

P.6.d.013 Self-reported impulsivity and gambling decision-making but not delay discounting covary with changing cocaine use across one year
, European Neuropsychopharmacology 25: S618-S619 (2015)

P.6.d.016 An old chemical that became a new psychoactive substance: study on O-Acetylpsilocin samples handled for analysis and raise of awareness
, European Neuropsychopharmacology 25: S620-S621 (2015)

P6.d.018 Delta9-tetrahydrocannabinol (Thc) and cannabidiol (Cbd) alone and in combination affect brain activity during rest
, European Neuropsychopharmacology 25: S621-S622 (2015)

P.6.d.019 Cannabinoid hyperemesis syndrome; a prevalence study
, European Neuropsychopharmacology 25: S622-S623 (2015)

P.6.d.022 Cognitive and emotional impairments in adults with attention-deficit/hyperactivity disorder and cocaine use: mutual effects of an unholy alliance
, European Neuropsychopharmacology 25: S624-S625 (2015)

P.6.e.001 When motivation becomes maladaptive similarities between drug addiction and obesity
, European Neuropsychopharmacology 25: S626-S627 (2015)

P.6.e.003 Epigenetic regulation of nociceptin/orphanin Fq and corticotropin-releasing factor system genes in frustration stress-induced binge eating
, European Neuropsychopharmacology 25: S627-S628 (2015)

P.6.f.003 Identification of food craving biomarkers and potential drug targets in obesity: clusterin and serum amyloid p-component
, European Neuropsychopharmacology 25: S628-S629 (2015)

P.6.f.004 Relationship of lifetime substance use and posttraumatic stress disorder among Turkish university students
, European Neuropsychopharmacology 25: S629-S630 (2015)

P.6.f.007 Efficacy of behavioural drug and risk counseling for patients in methadone maintenance treatment in Jakarta, Indonesia: a randomised clinical trial
, European Neuropsychopharmacology 25: S631-S632 (2015)

P.6.f.009 Shopping dependence among women with eating disorders
, European Neuropsychopharmacology 25: S632-S633 (2015)

P.6.f.012 Correlation between depression and thyroid function disturbance in women opiate addicts
, European Neuropsychopharmacology 25: S633-S634 (2015)

P.7.b.002 Epilepsy and Eeg paroxysmal abnormalities associated with autism spectrum disorders
, European Neuropsychopharmacology 25: S635-S636 (2015)

P.7.b.006 Abnormal functional architecture of amygdala-centered networks in adolescent posttraumatic stress disorder
, European Neuropsychopharmacology 25: S637-S638 (2015)

P.7.b.008 Progressive loss of gray matter volume in the frontal lobe is associated with decreased working memory performance over time in adolescent psychosis
, European Neuropsychopharmacology 25: S639-S640 (2015)

P.7.c.001 Correction of negative effects of acute normobaric hypoxia in rats with a synthetic analog of Acth
, European Neuropsychopharmacology 25: S640-S641 (2015)

P.7.d.001 A systematic review of lisdexamfetamine versus placebo in the treatment of child and adolescent Adhd
, European Neuropsychopharmacology 25: S641-S642 (2015)

P.7.d.004 Efficacy and safety of fluoxetine in the treatment of posttraumatic stress disorder in children and adolescents
, European Neuropsychopharmacology 25: S643-S644 (2015)

P.7.d.008 The impact of sleep on inattention, impulsiveness and cognitive failures
, European Neuropsychopharmacology 25: S644-S645 (2015)

P.7.d.009 Are antipsychotics a risk factor for type 2 diabetes in youth? A meta-analysis of incidence rates compared to healthy and psychiatric controls
, European Neuropsychopharmacology 25: S645-S646 (2015)

P.7.d.011 Results from a phase I proof-of-mechanism study with a vasopressin 1A receptor antagonist in autism spectrum disorder
, European Neuropsychopharmacology 25: S646-S647 (2015)

P.7.d.012 Relative efficacy of lisdexamfetamine dimesylate and osmotic controlled-release methylphenidate in attention-deficit/hyperactivity disorder patients
, European Neuropsychopharmacology 25: S647-S648 (2015)

P.7.d.014 Guanfacine extended release: daytime sleepiness outcomes from a phase 3 clinical study in adolescents with attention-deficit/hyperactivity disorder
, European Neuropsychopharmacology 25: S648-S649 (2015)

P.7.f.001 Relationship between depressed mood, body mass index, and body weight perception in Korean adolescents
, European Neuropsychopharmacology 25: S650-S651 (2015)

P.7.f.003 Public perspectives on pharmacological treatment of attention-deficit hyperactivity disorder
, European Neuropsychopharmacology 25: S651-S652 (2015)

P.7.f.005 Homeostatic brain correlates of acute social stress in excess weight adolescents
, European Neuropsychopharmacology 25: S652-S653 (2015)

P.8.b.001 A systematic review of the effectiveness of psychological interventions for adult sex-offenders in prisons, community clinics and forensic hospitals
, European Neuropsychopharmacology 25: S653-S654 (2015)

P.8.b.002 The effect of dietary intake of vitamin B6 on sleep quality and insomnia
, European Neuropsychopharmacology 25: S654-S655 (2015)

P.8.b.004 Correlation of group education with metabolic and psychosocial parameters in type 2 diabetes patients
, European Neuropsychopharmacology 25: S655-S656 (2015)

P.8.b.006 Binge eating disorder and bariatric surgery: a pilot study
, European Neuropsychopharmacology 25: S656-S657 (2015)

P.8.b.007 Relation between the presence of obesogenic behaviors and the outcome of bariatric surgery
, European Neuropsychopharmacology 25: S657-S658 (2015)

P.8.b.009 Inhaled loxapine for the acute treatment of agitation: clinical experience from eastern and northern Finland
, European Neuropsychopharmacology 25: S658-S659 (2015)

C.01.03 How to use anxiety, irritability, and agitation (Aia) for diagnosing mania with depressive symptoms patient cases
, European Neuropsychopharmacology 25: S661-S662 (2015)

C.02.02 Augmentation therapies in Mdd what are the unmet needs?
, European Neuropsychopharmacology 25: S662-S663 (2015)

C.02.04 Emerging clinical data in the adjunctive treatment of Mdd
, European Neuropsychopharmacology 25: S663-S664 (2015)

C.03.03 Pathways to improve cognitive dysfunction in depression
, European Neuropsychopharmacology 25: S664-S665 (2015)

C.05.02 Assessment of functioning and quality of life in schizophrenia and the relevance for clinical practice
, European Neuropsychopharmacology 25: S665-S666 (2015)

C.06.01 The treatment continuum in schizophrenia from the acute phase to maintenance
, European Neuropsychopharmacology 25: S666-S667 (2015)

C.08.03 Functioning and living well
, European Neuropsychopharmacology 25: S670-S671 (2015)

C.11.02 Need for earlier intervention in alcohol dependence evidence from a large cross-sectional study
, European Neuropsychopharmacology 25: S672-S673 (2015)

C.13.01 How I would manage a patient with Mdd and occupational impairment
, European Neuropsychopharmacology 25: S673-S674 (2015)

C.14.01 First witness cardiovascular risk
, European Neuropsychopharmacology 25: S674-S675 (2015)

(Epi)genetic regulation of fear sensitivity in mouse models of anxiety
, European Neuropsychopharmacology 26: S142-S143 (2016)

Drd2 gene polymorphisms association with severity of depressive symptoms and antidepressive therapy response in patients with depressive disorders
, European Neuropsychopharmacology 26: S173-S174 (2016)

New insights into the pharmacogenomics of antidepressant response from the Gendep and Stard* studies: results of high-density imputation
, European Neuropsychopharmacology 26: S177-S178 (2016)

Neural progenitor type-dependent differences in responses to metabotropic glutamate receptor 5 antagonist in the absence of fragile X mental retardation protein
, European Neuropsychopharmacology 26: S190-S191 (2016)

Heterogeneous effects of cholecystokinin on neuronal response properties in deep layers of rat barrel cortex
, European Neuropsychopharmacology 26: S219-S220 (2016)

Receptor-mediated activation of Galpha(q) and Galpha(i-3) assessed by [35S]GtpgammaS binding/immunoprecipitation assay in postmortem human brain membranes
, European Neuropsychopharmacology 26: S231-S232 (2016)

Boosting glutamatergic neurotransmission in infralimbic but not prelimbic cortex evokes antidepressant-like responses in rats through Ampa receptor activation
, European Neuropsychopharmacology 26: S243-S244 (2016)

Acute dose-response effects of Lsd in healthy humans
, European Neuropsychopharmacology 26: S248-S249 (2016)

Striatonigral-nigrotectal circuits regulate the expression of innate fear responses via cannabinoid receptor type 1 on Gabaergic neurons
, European Neuropsychopharmacology 26: S255-S256 (2016)

Regional brain volumes, diffusivity, and metabolite changes after electroconvulsive therapy for severe depression
, European Neuropsychopharmacology 26: S304-S305 (2016)

Serotonin 2A receptor agonist binding with [11C]Cimbi-36 in the human brain is unaltered by citalopram/pindolol and acute tryptophan depletion
, European Neuropsychopharmacology 26: S307-S308 (2016)

Interregional associations of Net binding in attention deficit/hyperactivity disorder; assessed with (S,S)-[18F]FmeNer-D2
, European Neuropsychopharmacology 26: S317-S318 (2016)

(Mis)use of prescribed stimulants in the medical student community: Motives and behaviors. A population-based cross-sectional study
, European Neuropsychopharmacology 26: S348-S349 (2016)

Mental-physical comorbidity in Korean adults: results from a nationwide general population survey in Korea
, European Neuropsychopharmacology 26: S351-S352 (2016)

Neurotrophin signaling in first episode psychosis: relation to response to antipsychotics after 1 year of follow-up
, European Neuropsychopharmacology 26: S361-S362 (2016)

Serotonin transporter methylation, neural responses to sadness and resting state functional connectivity: a study in adolescent monozygotic twins
, European Neuropsychopharmacology 26: S362-S363 (2016)

Plasma levels of 3-methoxy-4-hydroxyphenylglycol (Mhpg) can be a prediction marker of response to escitalopram treatment in Japanese major depressive disorder patients: Preliminary data
, European Neuropsychopharmacology 26: S391-S392 (2016)

Endoplasmatic reticulum stress and the unfolded protein response in bipolar disorder Xbp1 splicing, BiP and Chop gene expression
, European Neuropsychopharmacology 26: S420-S421 (2016)

Fluoxetine treatment affects the inflammatory response according to the quality of the living environment
, European Neuropsychopharmacology 26: S452-S453 (2016)

Plasma 3-methoxy-4-hydroxyphenylglycol level and the response to antidepressants
, European Neuropsychopharmacology 26: S455-S456 (2016)

The plasma proteome following electroconvulsive therapy: a role for pigment epithelium-derived factor (Pedf) in depression and treatment response?
, European Neuropsychopharmacology 26: S464-S465 (2016)

One-week administration of escitalopram decreases neural responses to self-referential processing in major depression
, European Neuropsychopharmacology 26: S465-S466 (2016)

Cortisol awakening response in patients with schizophrenia, first-episode psychosis and at-risk mental states: a meta-analysis
, European Neuropsychopharmacology 26: S487-S488 (2016)

Cellular reprogramming in schizophrenia: from disease modelling to the molecular bases of treatment response
, European Neuropsychopharmacology 26: S492-S493 (2016)

High Fsh:Lh ratio may be associated with poor response of negative symptoms in postmenopausal schizophrenia women
, European Neuropsychopharmacology 26: S538-S539 (2016)

Impact of nicotine consumption on antipsychotic response based on genetic variants of cytochrome P450 2D6 and multi-drug resistance 1 C3435T in schizophrenia
, European Neuropsychopharmacology 26: S552-S553 (2016)

High prevalence of underweight and under-nutrition in Japanese inpatients with schizophrenia: a nationwide survey
, European Neuropsychopharmacology 26: S586-S587 (2016)

Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder and obsessive-compulsive disorder?
, European Neuropsychopharmacology 26: S608-S609 (2016)

Alcohol dependent patients have blunted endogenous opioid release measured using [11C]carfentanil Pet and dexamphetamine challenge
, European Neuropsychopharmacology 26: S676-S677 (2016)

Genetic determinants of methylphenidate response in children with attention deficit hyperactivity disorder
, European Neuropsychopharmacology 26: S737-S738 (2016)

S.01.01 Autobahns in the brain: axonal transport and its disruption in neurological disorders
, European Neuropsychopharmacology 26: S1-S2 (2016)

P.1.001 Sterol regulatory element binding protein-2 (Srebp-2)-mediated cholesterol accumulation regulates mitophagy in amyloid precursor protein (App)/presenilin 1 (Ps1)/Srebp-2 mice
, European Neuropsychopharmacology 26: S2-S3 (2016)

P.1.002 Cognitive deficits due to chronic consumption of 9-tetrahydrocannabinol during adolescence: role of 5-Ht6-mTor pathway
, European Neuropsychopharmacology 26: S3-S4 (2016)

P.1.003 Gene networks and blood biomarkers of methamphetamine-associated psychosis: a preliminary integrative Rna-Seq report
, European Neuropsychopharmacology 26: S4-S5 (2016)

P.1.004 Novel neurotrophic strategy: interrogation of intracellular molecules regulating growth of midbrain dopaminergic neurons
, European Neuropsychopharmacology 26: S5-S6 (2016)

P.1.005 The stressed autophagy: chronic stress exacerbates Tau pathology by blocking autophagy clearance system
, European Neuropsychopharmacology 26: S6-S7 (2016)

P.1.006 Sweating the small stuff: chronic psychosocial stress regulates microRna expression in the hippocampus of the mouse
, European Neuropsychopharmacology 26: S7-S8 (2016)

P.1.007 Ketamine-induced plasticity in mouse-primary and human-iPsc-derived dopaminergic neurons involves D3R and mTor pathway
, European Neuropsychopharmacology 26: S8-S9 (2016)

P.1.008 Interaction of nitric oxide synthase 1 with its adaptor protein: effects on schizophrenia-related dendritic alterations
, European Neuropsychopharmacology 26: S9-S10 (2016)

P.1.009 Effects of caffeine, nicotine and their combination with haloperidol on Psd molecules: relevance to psychiatric diseases
, European Neuropsychopharmacology 26: S10-S11 (2016)

P.1.011 Changes in miR-212/132 expression in the hippocampus of rats subjected to olfactory bulbectomy
, European Neuropsychopharmacology 26: S11-S12 (2016)

P.1.012 Epigenetic regulation of oxytocinergic system during social fear conditioning
, European Neuropsychopharmacology 26: S12-S13 (2016)

P.1.013 Synthetic hallucinogen 5-methoxy-N,N-diisopropyltryptamine and its action in the rat brain
, European Neuropsychopharmacology 26: S13-S14 (2016)

P.1.017 Gprin1, a new 5-Ht6 receptor partner involved in its constitutive activity and receptor-induced neuronal differentiation
, European Neuropsychopharmacology 26: S16-S17 (2016)

P.1.018 Molecular and functional characterisation of the glycine-receptor system in the mouse locus coeruleus nucleus
, European Neuropsychopharmacology 26: S17-S18 (2016)

P.1.019 Functional investigation of the Aldh2 promoter: a regulatory genetic-epigenetic interplay
, European Neuropsychopharmacology 26: S18-S19 (2016)

P.1.020 Ketamine inhibits long-term potentiation and promotes long-term depression in the nucleus accumbens
, European Neuropsychopharmacology 26: S19-S20 (2016)

P.1.021 The G-immunoglobulins of schizophrenic patients demonstrate proteolytic activity
, European Neuropsychopharmacology 26: S20-S21 (2016)

P.1.022 The type of stress matters: different stressors can lead to different biological profiles
, European Neuropsychopharmacology 26: S21-S22 (2016)

S.02.01 How the gut influences the brain: the intestinal microbiome as a new dimension for understanding mental health
, European Neuropsychopharmacology 26: S23-S24 (2016)

S.02.02 The making and breaking of memory: from molecules to networks
, European Neuropsychopharmacology 26: S24-S25 (2016)

P.2.001 Reducing effect of saikosaponin A on alcohol self-administration in rats: possible involvement of the Gabab receptor
, European Neuropsychopharmacology 26: S25-S26 (2016)

P.2.002 Rac1 Gtpase and Pak activities in lateral amygdala constrain fear memory formation
, European Neuropsychopharmacology 26: S26-S27 (2016)

P.2.006 Prenatal testosterone activity determines adult alcohol drinking and morphology in mice
, European Neuropsychopharmacology 26: S28-S29 (2016)

P.2.007 A novel self-adjusting delay discounting procedure for the study of choice impulsivity in rats
, European Neuropsychopharmacology 26: S29-S30 (2016)

P.2.008 Effect of acute and chronic administration of a new psychoactive drug, methoxetamine, on behaviour, mood and reward
, European Neuropsychopharmacology 26: S30-S31 (2016)

P.2.010 Ketamine inhibits the activity of thalamic neurons in anesthetized rats
, European Neuropsychopharmacology 26: S31-S32 (2016)

P.2.011 The role of ascending ventral tegmental area projections in impulsivity and attention
, European Neuropsychopharmacology 26: S32-S33 (2016)

P.2.012 Glutamatergic manipulation in spatial search processes: advanced cognitive neurophysiological analysis in rats
, European Neuropsychopharmacology 26: S33-S34 (2016)

P.2.013 Effects of Mk-801 and medial prefrontal cortex lesions on cognitive flexibility in a novel task based on the change of interval schedules
, European Neuropsychopharmacology 26: S34-S35 (2016)

P.2.014 Lithium ameliorates manic-like behaviour in Ank3+/- mice via the kinesin cargo system: a protein interaction network view
, European Neuropsychopharmacology 26: S35-S36 (2016)

P.2.015 Chronic effects of biased 5-Ht1A receptor agonists on object pattern separation performance and hippocampal plasticity
, European Neuropsychopharmacology 26: S36-S37 (2016)

P.2.016 Muscimol effectively reverses impaired spatial memory in Alzheimer's disease-type streptozocin icv rat model
, European Neuropsychopharmacology 26: S37-S38 (2016)

P.2.018 Role of 5-alpha reductase in the pathophysiology of L-Dopa induced dyskinesia
, European Neuropsychopharmacology 26: S38-S39 (2016)

P.2.019 Improvement of experimental focal ischemic outcomes by triflusal
, European Neuropsychopharmacology 26: S39-S40 (2016)

P.2.020 The novel antipsychotic brexpiprazole partly reverses a disruption of thalamocortical function induced by phencyclidine
, European Neuropsychopharmacology 26: S40-S41 (2016)

P.2.021 The endocannabinoid system: possible new pharmacological target in the treatment of anorexia nervosa
, European Neuropsychopharmacology 26: S41-S42 (2016)

P.2.022 Attaining in vivo selectivity of positive modulation of a3 Gaba-A receptors in rats: a hard task
, European Neuropsychopharmacology 26: S42-S43 (2016)

P.2.023 Role of levo-dihydroxyphenylalanine on cocaine-taking and cocaine-seeking behaviour in rats
, European Neuropsychopharmacology 26: S43-S44 (2016)

S.03.01 Why white matter matters: oligodendrocytes, myelin and brain connectivity - disruption linked to schizophrenia
, European Neuropsychopharmacology 26: S45-S46 (2016)

P.3.001 Influence of habitual negative affect on processing of negative facial stimuli in alcoholic patients
, European Neuropsychopharmacology 26: S46-S47 (2016)

P.3.002 Glutamatergic and Gabaergic gene-sets in Adhd: association to overlapping traits in Adhd and autism
, European Neuropsychopharmacology 26: S47-S48 (2016)

P.3.004 Neuroimaging derived polygenic scores predict outcomes to psychotherapy and medication treatments for depression
, European Neuropsychopharmacology 26: S48-S49 (2016)

P.3.005 Is diagnosis indeed prognosis? 12 months outcome for schizophrenia, schizophreniform and schizoaffective disorder
, European Neuropsychopharmacology 26: S49-S50 (2016)

P.3.006 Effects of visual adaptation on perception of and satisfaction with own body size: two randomised studies
, European Neuropsychopharmacology 26: S50-S51 (2016)

P.3.007 Modulation of the approach-avoidance tendencies of persons with high social anxiety by the neuropeptide oxytocin
, European Neuropsychopharmacology 26: S51-S52 (2016)

P.3.008 Attenuated resting-state default mode network connectivity in remitted depression after sad autobiographical recall
, European Neuropsychopharmacology 26: S52-S53 (2016)

P.3.009 Quitting cannabis decreases but does not eliminate psychosis risk: evidence from a 7 years large population-based cohort
, European Neuropsychopharmacology 26: S53-S54 (2016)

P.3.010 Endogenous plasma testosterone in healthy men is negatively associated with hippocampal serotonin receptor 4 binding
, European Neuropsychopharmacology 26: S54-S55 (2016)

P.3.011 Attenuated cortisol response to blockade of the mineralocorticoid receptor in depressed patients
, European Neuropsychopharmacology 26: S55-S56 (2016)

P.3.012 Sensitisation effects induced by d-amphetamine in healthy humans measured with the D2,3 radioligand [11C]-(+)-Phno
, European Neuropsychopharmacology 26: S56-S57 (2016)

P.3.013 Using publicly available data to investigate causal associations between substance use and mental health
, European Neuropsychopharmacology 26: S57-S58 (2016)

P.3.015 Dna methylation signatures of susceptibility to panic disorder
, European Neuropsychopharmacology 26: S58-S59 (2016)

P.3.016 Cyp2C19 enzymatic capacity predicts hippocampal volume in healthy subjects
, European Neuropsychopharmacology 26: S59-S60 (2016)

P.3.017 Evaluation of cognitive functioning during antidepressant treatment in young patients with severe major depressive disorder
, European Neuropsychopharmacology 26: S60-S61 (2016)

P.3.018 Schizophrenia susceptibility gene Cacna1C associates with microstructure of fornix
, European Neuropsychopharmacology 26: S61-S62 (2016)

P.3.019 Development of psychopathology in deployed armed forces is related to increasing plasma Gaba levels
, European Neuropsychopharmacology 26: S62-S63 (2016)

P.3.020 Is plasma neuropeptide Ya susceptibility marker for posttraumatic stress symptoms over time?
, European Neuropsychopharmacology 26: S63-S64 (2016)

P.3.021 Long-term signature after stress early in life by using mRna-miRna integration approach in rats and humans
, European Neuropsychopharmacology 26: S64-S65 (2016)

P.3.022 Repeated intranasal oxytocin administration as early preventive intervention for Ptsd: a randomized controlled trial
, European Neuropsychopharmacology 26: S65-S66 (2016)

P.3.023 Effects of the potential lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance spectroscopy study
, European Neuropsychopharmacology 26: S66-S67 (2016)

P.3.024 Translational neuroimaging reveals differential effects of chronic ketamine on brain macrostructure in humans and mice
, European Neuropsychopharmacology 26: S67-S68 (2016)

P.3.025 Brain-derived neurotrophic factor associates with gray matter volumes and early adverse experiences in bipolar disorder
, European Neuropsychopharmacology 26: S68-S69 (2016)